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ABSTRACT
MIRNA-21 HAS ANTI-INFLAMMATORY EFFECTS IN THE MACROPHAGE
RESPONSE TO PERITONITIS
Rebecca Elise Barnett
July 21, 2014

This project investigated the role of miRNA-21 in the macrophage response to
peritonitis; with the goal of understanding whether the associated mechanism
has potential benefits in the clinical treatment of peritonitis. A novel therapeutic
intervention in the treatment of peritonitis could modulate the host immune
response to decrease an exaggerated pro-inflammatory innate response and
then prevent or ameliorate the development of sepsis and organ failure. We
found the following:
1. MiRNA-21

expression

increases

in

peritoneal

macrophages after

lipopolysaccharide (LPS) stimulation.
2. Over expression

of

miRNA-21

decreases TNF-α

secretion

from

macrophages after LPS stimulation. Suppression of miRNA-21 expression
results in increased TNF-α and IL-6, together with decreased IL-10 after
LPS stimulation.
v

3. Protein targets of miRNA-21 after LPS stimulation were not significantly
different following suppression of miRNA-21.
4. NF-κB and ERK signaling was unaffected by suppression of miRNA-21.
5. MiRNA-21 is beneficial in survival following induction of peritonitis with
LPS.
6. MiRNA-21 does not affect survival following induction of peritonitis with
cecal ligation and puncture.

These findings demonstrate that although miRNA-21 is beneficial in
modulating the macrophage response to LPS, the effect is buried in the
multiple pathways activated after the clinically more relevant model of cecal
ligation and puncture. The improved understanding of the anti-inflammatory
effects of miRNA-21 in the macrophage response to peritonitis may result in a
targeted therapy to intervene in clinical peritonitis.

vi
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CHAPTER I
INTRODUCTION
Peritonitis is regularly seen as part of clinical surgical practice. It can have
multiple causes, resulting in bacterial infection within the peritoneal cavity of the
abdomen. These include appendicitis, diverticulitis with perforation, and
perforated bowel from a variety of other causes. Patients with peritonitis can
have a variable disease course, from a mild, self-contained infection, through a
whole body septic response potentially leading to multi-organ failure and
potential fatality. It is a frequent cause for admission to the hospital and the
surgical intensive care unit 1. Although improvements in critical care have led to
more patients surviving, there has been little change in the treatment of
peritonitis in the last 50 years 2. The mainstay remains 1) source control by
removal, debridement, and/or drainage of infected and necrotic tissue; 2)
antibiotics directed at Gram negative pathogens including anaerobes; and 3)
supportive treatment of homeostatic functions in various organs such as the
lungs, liver, kidneys, heart and gut.
Mortality is directly associated with an exaggerated pro-inflammatory innate
response with development of sepsis and organ failure

3

. Several immune

modulators have undergone clinical trials in recent years with the aim of
manipulating the immune response to the benefit of the patient, but none have
1

successfully been able to change patient outcomes. The purpose of this work is
to investigate specific mechanisms by which the response of peritoneal
macrophages to endotoxin and bacterial infection are regulated and identify
potential routes for therapeutic intervention.

2

CHAPTER II
GENERAL OVERVIEW
A. Clinical Importance of Peritonitis
Peritonitis is inflammation of the lining of the peritoneal cavity that occurs in
response to local irritation or infection. It can be categorized into primary,
secondary and tertiary

4, 5

. Primary or spontaneous bacterial peritonitis is

relatively rare and occurs in ascites and liver failure. Secondary bacterial
peritonitis is usually caused by a perforation, when enteric bacteria from the
bowel are released into the peritoneal cavity and is our primary focus for these
studies. Tertiary peritonitis is the persistence of bacteria despite adequate
therapy, consisting of source control, drainage of any abscess and use of
appropriate antibiotics 4, 6. Chemical peritonitis is less common, and occurs when
blood, acid, bile, pancreatic juice, or other bodily fluids are released into the
peritoneal cavity in the absence of infection. This usually occurs in the setting of
surgical complications and trauma 7.
Secondary bacterial peritonitis is a common cause of surgical sepsis and has
multiple etiologies, stemming from ischemia or perforation of the bowel that leads
to enteric bacteria within the peritoneal cavity 2. The most common causes are
inflammatory processes such as diverticulitis and appendicitis, but can also

3

include traumatic injuries and colon cancers eroding through the bowel wall.
Peritonitis can be a spectrum of disorders, ranging from a contained local
irritation, such as that associated with a benign appendicitis to pancreatic
necrosis and intestinal ischemia that are often associated with substantial
morbidity and mortality

5, 8

. Several scoring systems such as the Mannheim

Peritonitis Index and the Acute Physiology and Chronic Health Evaluation
(APACHE) II score have evolved to try to predict those with a risk of increased
morbidity and more complicated disease course

4, 9-13

.

The treatment of peritonitis has remained unchanged for the last 50 years;
antibiotics directed at the offending gram negative aerobic and anaerobic
bacteria and source control of the infection by open or laparoscopic resection,
debridement, and drainage or percutaneous drainage. A recent Cochrane review
concluded that no specific recommendations could be made about the first line
antibiotics, as all included in the studies were equivalent, and included antibiotics
active against gram negative aerobes and anaerobes

14

. Despite treatment,

peritonitis may progress to sepsis, a systemic inflammatory response to a source
of infection, consisting of fever, tachycardia, tachypnea, and leukocytosis and
multi-organ

dysfunction.

The

Dutch

registry

for

intensive

care

shows

approximately 2.5% of all intensive care admissions are due to intra-abdominal
infection combined with sepsis 15.

4

Despite clinically proven treatment and the ability to predict those with a higher
risk of morbidity and mortality, it remains unknown why some patients are unable
to contain and eliminate such an infection, resulting in a persistence of bacteria in
the peritoneum. Some have theorized that this is because of a failure of the host
immune response to clear the infection, and that augmentation or modulation of
the immune response may serve to enhance the clearance of bacteria in these
patients. Some patients go onto a persistent inflammatory state and develop
organ failure, despite adequate source control, which is also a source of
significant morbidity and mortality. Several immune-modulators have undergone
clinical trials following success in a lab environment, however none have been
successful in a clinical setting 16, 17.

B. Immune Response Overview
The immune response occurs in 3 phases: 1) The immediate innate (0-4 hours)
response, which is recognition of the invading pathogen or tissue injury by
preformed, non-specific and broadly specific effectors. 2) The early innate (4-96
hours) which deals with the recognition of microbial-associated molecular
patterns and in the inflammation, recruitment and activation of effector cells; and
3) the adaptive (>96 hours) which consists of recognition by B and T cells and
clonal expansion and differentiation into effector cells

5

18, 19

. All these process act

synergistically to remove the infectious agent. This thesis will deal primarily with
the early innate immune response in the first 96 hours of an infection.
The innate immune system has evolved to be the first line of response to
pathogens. It consists of the mechanical barriers to infection such as that seen in
the skin epithelium and the mucosa of the bowel wall. The activation of
complement and coagulation cascades impairs pathogen function, as well as
activating the cellular component of the innate immune system

19

. Pathogen

associated molecular proteins (PAMPs) and damage associated molecular
proteins (DAMPs) are released in response to pathogen invasion and are
recognized by Pattern Recognition Receptors (PRRs) on the surface of immune
cells

20

. This combination of bacterial proteins and those released by damaged

cells binds to PRR receptors such as Toll-like receptors (TLR), NOD-like
receptors and Mannose-Binding Lectin that can be either cell associated in the
membrane or cytosol or secreted to stimulate the immune system 19, 21.
The major cells of the innate immune system are the macrophage and neutrophil
both of which play an important role in the phagocytosis of bacteria, but the
macrophage is the key orchestrator of the local reaction

19, 22

. Macrophages

reside in the tissues and release mediators such as, cytokines and chemokines
to induce inflammation as well as directly attacking microbes via release of free
radicals, proteolytic enzymes and phagocytose invading pathogens

23, 24

. This

release stimulates the influx of neutrophils and subsequently monocytes and

6

macrophages from the peripheral circulation to assist in fighting the infection. The
third main function of macrophages is antigen processing after phagocytosis and
presentation to other immune cells which initiates the adaptive immune response
19

with eventual specific antibody production

.

This pro-inflammatory response is followed by a regulated anti-inflammatory
response which dampens down any excessive inflammation, to reduce the
damage to surrounding normal tissue

19

. Often there is a dysfunctional early

innate immune response that does not respond appropriately to the infection,
which can lead to an imbalance in the pro and anti- inflammatory responses,
which is detrimental to the health of the organism

25

.

C. Macrophages
Resident peritoneal cells include the mesothelial lining, mast cells and
leucocytes. The human peritoneal resident leucocyte population comprises 4590% macrophages, 10-47% lymphocytes and the rest NK cells, dendritic cells
and neutrophils

26

. The mesothelial lining and macrophages are the main source

of chemokines and cytokines that attract neutrophils and circulating monocytes to
the peritoneum

18

. Cytokines bind to cell surface receptors on target cells,

inducing intracellular signaling cascades to induce, or inhibit cytokine-regulated
genes in the nucleus, thus manipulating cell activity. IL-10 produced by
macrophages inhibits neutrophil recruitment and chemokine generation, which in
7

turn inhibits pro-inflammatory cytokine release

27

. Diffusion of inflammatory

mediators TNF-α and IL-1β from the circulation plays an important role in the
pulmonary activation of resident macrophages which results in the associated
lung disease and neutrophil infiltration seen in animal models

28, 29

.

Toll-like Receptor signaling
Host immune cells recognize foreign microbial pathogens by pattern recognition
receptors located on their surface. The most studied of these are the toll-like
receptors of which there are 12 in mice, and 10 in humans; most are located
within the cell membrane, though TLR-3, -7, -8, -9, -11 and -13 are within the cell
cytosol

19

. TLR-4 is found on the cell membrane and responds to bacterial

products such as lipopolysaccharide (LPS), derived from the outer membrane of
gram-negative bacteria

30

. Ligand binding to TLR-4 results in the activation of

intracellular signaling and release of cytokines (Figure 1). In the unstimulated
cell, the transcription factor, nuclear factor kappa B (NF-κB) is sequestered in the
cytoplasm by inhibitory IκB proteins

31

. When LPS binds to TLR-4, myeloid

differentiation primary response gene 88 (MyD88) is activated to initiate intracellular signaling pathways. This leads to the phosphorylation of IκB by IκB
kinases (IKKs), its subsequent degradation and allows the dissociation of NF-κB
from the inhibitory complex and its nuclear translocation to stimulate gene
expression

32

. This stimulates the transcription of the pro-inflammatory cytokines

notably Tumor Necrosis Factor-α (TNF-α) and Interleukin-6 (IL-6) 33, 34. TLR-4

8

Figure 1: Toll-like Receptor-4 signaling

Overview of the Toll-Like Receptor 4 (TLR-4) signaling through MyD88
dependent and independent pathways. Lipopolysaccharide (LPS),TRIF-related
adapter molecule (TRAM), TIR-domain-containing adaptor-inducing interferon β
(TRIF), Myeloid Differentiation Primary Response Gene 88 (MyD88), IL-1
Receptor Associated Kinase (IRAK), TNF-Receptor Associated Factor 6
(TRAF6), Mitogen Activated Protein Kinases pathway (MAPK), Extracellular
Signal Related Kinase (ERK), c-Jun N-terminal Kinase (JNK), Inhibitory Kappa
Kinase (IKK), Inhibitory Kappa Beta (Iκβ), Nuclear Factor Kappa Beta (NF-κB),
Interleukin-10 (IL-10) and Tumor Necrosis Factor-α.

9

also activates a MyD88-independent, TIR-domain-containing adaptor-inducing
interferon β (TRIF) dependent pathway

32

. MyD88-mediated signaling involves

the activation of IL-1-Receptor associated kinases (IRAKs)

35

. IRAKs activate

TRAF6 (TNF-Receptor Associated Factor; central signaling protein of TLR-4
pathway), which catalyses lysine 63 (K63) –linked ubiquitin chains. This TRAF6
mediated ubiquitination is important in amplifying TLR-4 signaling by stimulating
multiple downstream pathways, through IKK,

NF-κB and the MAPKs,

extracellular signal-related kinase (ERK), JNK and p38 to induce the genes
coding for inflammatory cytokines 36, 37.

D. MicroRNAs
MicroRNAs (miRNAs) are short non-coding RNAs, 22-25 nucleotides long, which
act to inhibit protein production

38

. MiRNA are formed in the nucleus as pri-

miRNA, cleaved into the hairpin shaped pre-miRNA by Drosha and exported
from the nucleus into the cytoplasm by Exportin-1 39. In the cytoplasm the miRNA
are further cleaved by Dicer and incorporated into the RNA-induced silencing
complex (RISC). The RISC then binds to the 3’ untranslated region (UTR) of
messenger RNA (mRNA) to inhibit translation of proteins

40

. If the sequences are

100% complementary, then the mRNA is degraded, if the sequence is only 80%
complementary, the mRNA remains intact, but unable to be translated into
protein. MiRNA act as post-transcriptional modulators of protein translation
10

41

.

There are >1000 miRNAs documented, each with hundreds of potential targets
based on mRNA sequences, often experimentally unverified. There are multiple
miRNAs known to target the TLR-4 signaling pathway 42.
There has been a substantial increase in miRNA studies since the early
discoveries made by Fire and Mellow

43

. The essential role that miRNAs play in

cell function and their possibilities as stable biomarkers mean that there is much
still to learn about the influence of miRNAs. For example miRNA and
transcription factors both regulate inflammation, and now there are examples of
transcription factors regulating miRNA expression directly

40, 44

.

As promoter

regions of miRNAs are identified, a more focused understanding of their
transcriptional regulation will emerge 45.

MicroRNA-21
MiRNA-21 has been the object of multiple studies due to its high abundance and
significant role in cardiovascular injury, cancer progression and metastasis

46

.

The targets of miRNA-21 have roles in apoptosis, cell proliferation, cell migration,
and invasion, and it has been shown to be up-regulated in multiple cancer types
including but not limited to breast, lung, colorectal, hepatocellular, pancreatic and
diffuse large B-cell lymphoma 46-49. MiRNA-21 has also been found in the plasma
of patients with colorectal cancer

50

. MiRNA-21 is located on chromosome 17 in

the 10th intron of the protein coding gene TMEM49 whose function is currently
11

unknown. It has its own promoter and expression is not affected by the TMEM49
45

promoter

. Transcription is stimulated by NF-κB and knockdown of NF-κB by

siRNA and inhibitors has shown to reduce expression of miRNA-21 in a nicotineinduced cell proliferation model of gastric cancer

44, 51

. LPS induces miRNA-21

via TLR-4, MyD88 and NF B, which has a binding site in the miRNA-21 promoter
region

52

. The role of miRNA-21 in the immune system is still under active

investigation, though it is believed to be involved in the transition between the pro
and anti-inflammatory phases of the early innate immune response. The miRNA21 targets that may contribute to this are Programmed cell death protein 4
(PDCD4), Pelino 1 (Peli1), and Sprouty (SPRY) proteins 1, 2 and 4 53.

Programmed Cell Death Protein 4
PDCD4 has been validated as a target of miRNA-21 by independent groups

51, 54-

56

. There is a single highly conserved miRNA-21 target site within the 3’UTR

region, and it’s regulation by miRNA-21 has been reported in both human and
murine cancer models

52

.

Sheedy et al, show PDCD4 is a key step in the

negative regulation of the inflammatory response to LPS

51

. PDCD4-/- mice have

been shown to have a lower mortality to LPS than PDCD4 +/+ mice, associated
with lower IL-6 and higher IL-10 levels 51.

12

Pelino 1
There are 3 mammalian homologs of the Pelino (Peli) proteins
has so far been described as a likely target of miRNA-21

57

but only Peli1

53

. The Peli proteins,

like TRAF6, function as E3 ubiquitin ligases and interact with the IRAKs, inducing
ubiquitination of IRAK1, and thus have been linked to the regulation of TLR-4
MyD88-dependent signaling

57, 58

as well as T cell activation

59, 60

. Peli has also

been demonstrated to be critical in TLR-3 activation of IKK and NF-κB, through
interactions in the TRIF pathway

36

. Peli interacts with TRIF-signaling adaptor

kinase RIP1 and mediates RIP1 ubiquitination, a key step in the TRIF-dependent
IKK-signaling pathway, and is critical in TRIF-dependent TLR signaling, though
non-essential for MyD88-dependent TLRs

36

. Peli1 has shown to be important in

TLR-4-mediated gene induction, though only partially required for LPS stimulated
activation of IKK and NF-κB (Figure 1). Peli1 is a proven target of miRNA-21 in
liver regeneration, where Peli1 mRNA was inversely correlated with miRNA-21
levels

61

. Peli1 mRNA and protein expression is increased in macrophages that

are stimulated by the TLR-4 ligand LPS, via a TRIF-dependent pathway, and
independent of the MyD88-dependent pathway

62

. The IKK-related kinases or

IRAK1 activate Peli1 on macrophage stimulation through the TLR MyD88
pathway and via TNF-α 63.

13

Sprouty
The Sprouty proteins were first described in 1998 as an inhibitor of fibroblast
growth factor in Drosophilia 64. There are four 4 isoforms in mammals, and all are
postulated targets of miRNA-21. Sprouty proteins inhibit signaling by receptor
tyrosine kinases affecting the activation of MAPK. Srpy1, 2 & 4 block the
activation of ERK (extracellular signal related kinase) in cells stimulated by
growth factors, different points in the signaling cascade depending on the
biological context

65-67

. In mouse fibroblasts SPRY1 and 2 inhibit ERK/MAPK

signaling at the level of Ras activation, in human epithelial cells, SPRY2 acts on
RAF1 as does mammalian SPRY4

68-70

. All sprouty isoforms inhibit the ERK

pathway by themselves, but heterodimers and homodimers have enhanced
inhibition

71, 72

. In cardiac fibroblasts increased miRNA-21 is associated with

decreased expression of SPRY1 and up-regulation of the ERK cascade 73.

Signaling molecules NF-κB and ERK
There are five members of the mammalian NF-κB family, RElA, RelB, c-Rel, p50
and p52, which combine to form multiple dimeric complexes and activate target
genes by binding to the enhancer element κB

74

. As mentioned above, these

proteins are sequestered in the cytoplasm by IκB proteins until the IκB proteins
are phosphorylated and degraded by the proteasome allowing the NF-κB
proteins to translocate to the nucleus to effect gene expression
14

75, 76

. MiRNA-21

overexpression was associated with a ~40% decrease in NF-κB activity in HEK293 cells 61.
ERK is one arm of the MAPK signaling pathway, triggered in response to TLR
signaling

77, 78

. The relationship between ERK activation and IL-10 production is

not a simple one. Higher levels of ERK activation have been linked to higher IL10 production 79.

Cytokines
Tumor Necrosis Factor –α
TNF–α is an important pro-inflammatory cytokine, the first one to be discovered
as such with a plethora of effects when injected into animals including humans
including fever, hypotension, metabolic acidosis and capillary leak

80-82

. TNF-α

plays a regulatory role in promoting local and systemic bacterial clearance

83

.

IL-6
Interleukin-6 (IL-6) is released from macrophages in response to pathogens. It
acts both locally to activate lymphocytes and increase antibody production, as
well as systemically to induce fever, the production of acute phase proteins from
the liver and neutrophil mobilization and migration to the focus of infection

19, 83

.

IL-6 correlates with mortality and IL-6 levels 6 hours from injury in a CLP model

15

predicts mortality

84

and has been shown to be the best biomarker of mortality in

clinical sepsis 85. IL-6 is induced by NF B and augmented by PDCD4 51.
IL-10
Interleukin-10

(IL-

10),

previously

named

cytokine

synthesis

inhibitory

factor (CSIF), IL-10 suppresses both macrophage and dendritic cell function,
including the ability to present antigens and the production of pro-inflammatory
cytokines (IL-1β, TNF-α, and IL-12)

79

. IL-10, as an important part of an anti-

inflammatory response, limits the immune and inflammatory responses to
pathogens, which might otherwise result in collateral damage to the host
organism

86, 87

. IL-10 is constitutively transcribed in many cells, though post-

transcription regulations make the protein levels tightly regulated

88

. Loh et al,

show that PDCD4 inhibits translation by blocking the binding of translation
initiation factor eIF4Gc to eIF4A in an inactive conformation

89

. This is thought to

be part of the mechanism by which IL-10 is suppressed by PDCD4, as PDCD4
inhibits the cap-dependent translation of mRNAs with complex 5’ untranslated
regions (UTRs), which include IL-10.

E. Peritonitis Models
The clinical infection of peritonitis that we see in our human surgical patients has
been modeled using various several different methods. Each experimental model

16

has its value, depending on the hypothesis of the experiment. The use of animal
models, which while not exactly the same physiologically as human, allows in
vivo investigation into the mammalian physiology of normal or pathologic
processes, and well as to investigate mechanisms of disease. These models
may also serve to test the ability of an intervention to interrupt normal or
pathologic processes and aid in the preclinical testing of potential therapeutic
agents 16.
The most common models of experimental peritonitis are cecal ligation and
puncture (CLP) and endotoxin (LPS)
animals

due

to

cost

16

. These are frequently performed in small

considerations

and

the

numbers

required

for

experimentation. The defined characteristics of different strains and availability of
genetic variants such as gene knockouts also make mice a useful model for
peritonitis experiments.
Lipopolysaccharide
Lipopolysaccharide (LPS) or endotoxin is a common model of inflammation,
especially in the mouse and has been a laboratory workhorse for decades. LPS
is considered to be an important inducer of the septic response and
intraperitoneal LPS is more likely to induce a hyperdynamic cardiovascular
response than intravenous (IV) administration and is thus a better model for the
human condition

16

. Induction of LPS peritonitis is simple, requiring only an intra-

peritoneal injection of the desired concentration of LPS in a standard carrier
17

volume, and can be performed readily with minimal practice. While this model
gives a bolus of bacterial protein, and it has less clinical relevance because
patients have a septic focus that slowly seeds bacteria into the body 90.
Cecal Ligation and Puncture
Cecal Ligation and puncture (CLP) is a well-established murine model of
peritonitis that more closely models human peritonitis, as it combines the entry of
enteric bacteria into the peritoneum, together with a foreign body reaction and an
ischemic focus

16

. A small incision is made in the abdomen, and the cecum

externalized. The distal segment is ligated, ~1cm from the cecal pole and a
puncture made in the ligated segment. The cecum in the mouse is a blind-ended
tube, so no obstruction is caused by ligation of the bowel, when properly
performed. The bowel is then returned to the abdomen and the peritoneum and
skin closed in layers. The severity of the model can be varied with the length of
bowel ligated and the size and number of punctures in the cecum

91

. Cecal

Ligation and puncture, in contrast to the LPS model, is a more time consuming
cause of peritonitis, requiring superior surgical skills, and a more precise
technique in order to consistently perform the same operation multiple times
within the inherent variability in mouse anatomy. These animals develop an initial
hyperdynamic cardiovascular response, similar to that seen in patients with
increased cardiac output and decreased systemic vascular resistance

90

. This

develops into systemic bacteraemic infection and sepsis, which progressively
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undergoes cardiovascular collapse due to septic shock and death days after the
initial insult, similar to the condition seen in peritonitis patients who die from
multiple organ failure days after the onset of infection.
We propose to use both established models of peritonitis to examine the effect of
miRNA-21 on both mechanistic and clinically relevant patterns of intra-abdominal
infection. Existing data show that miRNA-21 acts on the TLR-4 pathway in
response to LPS. If we are able to modify the balance of pro- and antiinflammatory immune response through manipulating the cytokines released in
response to infectious stimuli, we may be able to affect survival and initiate the
beginning of a new potential therapy for patients with peritonitis.
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CHAPTER III
HYPOTHESIS, SPECIFIC AIMS AND EXPERIMENTAL PLAN

A. Key Objective
To investigate the role of miRNA-21 in the macrophage response to
peritonitis, and identify whether the associated regulatory mechanisms
have potential benefits in the clinical treatment of peritonitis.

B. Hypothesis
We hypothesize that the outcome of peritonitis can be modulated by
miRNA-21 through down regulation of NF-κB signaling that will affect
macrophage cytokine release, to diminish local inflammation.
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C. Specific Aims
1: To establish a time course of miRNA-21 expression in peritoneal
macrophages following an infectious insult, either lipopolysaccharide or
cecal Ligation and Puncture.
2: To examine the mechanisms by which miRNA-21 regulates the
inflammatory response.
3: To investigate the effects of miRNA-21 on macrophage cytokine
production
4: To ascertain the effect of miRNA-21 knockout on survival in in vivo
models of peritonitis - lipopolysaccharide or cecal ligation and puncture.

D. Experimental Plan
The overall goal of this project is to investigate the role of miRNA-21 in the
macrophage response to peritonitis. We will establish the pattern of
miRNA-21 expression and cytokine secretion from primary peritoneal
macrophages. We will examine how modulation of miRNA-21 expression
changes cytokine secretion. If we see a difference, we will investigate
which targets of miRNA-21 that act on the TLR-4 signaling pathway are
different between bone marrow derived macrophage cell lines from
miRNA-21+/+ and miRNA-21-/- mice. Finally we will investigate the clinical
potential for the use of miRNA-21 as a novel agent in peritonitis by
comparing the survival of miRNA-21+/+ and miRNA-21-/- mice in LPS and
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cecal ligation and puncture models of peritonitis. An outline is shown in
Figure 2.

E. Methods
i.

Mice
Approvals for the study protocols were obtained from the Robley Rex
Veteran Affairs Medical Center and University of Louisville Institutional
Animal Care and Use Committees (VA: che37, UofL: 11064).
Wild-type Mice for Peritoneal Macrophage Experiments
Male 6 week old C57BL/6 mice obtained from Jackson Laboratories (Bar
Harbor, ME) were housed with food and water ad libitum according to
IACUC guidelines.
MiRNA-21 Knockout Mice and Wild Type Controls
The gene targeting of miRNA-21 in mice was performed by inGenious
Targeting Laboratory (iTL), Inc (Ronkonkoma, NY) as previously
described

92

. Briefly a targeting vector was constructed and transfected

into hybrid embryonic stem cells by electroporation. Positive recombinant
clones were identified by polymerase chain reaction (PCR). Targeted iTL
BA1 hybrid embryonic stem cells were microinjected into C57BL/6
blastocysts. Resulting chimeras were mated to wild-type C57BL/6 mice to
generate F1 heterozygous offspring with germline transmission. Mice were
bred within our breeding facility. Genotype was confirmed by PCR prior to
experimentation.
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Figure 2: Outline of Study

The study begins with the peritoneal macrophage response, and then utilizes
both miRNA-21+/+ and miRNA-21-/- bone marrow macrophage cell lines to
delineate the impact of miRNA-21 on the cellular response to lipopolysaccharide.
In vivo models of peritonitis are then used to assess the effect of miRNA-21 in a
whole body situation.
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Bone Marrow Macrophage Cell Lines
Immortalized macrophage cell lines (BMM) were established by infecting
the bone marrow of miRNA-21+/+ and miRNA-21-/- mice with the murine
recombinant J2 retrovirus containing the v-myc and v-ref oncogenes as
previously described

33, 93, 94

. Cells were cultured in RPMI-1640 medium

with 5% Fetal Bovine Serum, 1% L-glutamine, 1% HEPES and 0.1%
gentamicin (all Sigma Aldrich) at 37°C in a humidified incubator with 5%
CO2.

ii.

Harvest of Peritoneal Cells
Naïve mice were anaesthetized with 2-3% isoflurane (Butler Schein,
Dublin, OH) and the abdomen lavaged with 3mL of heparinized phosphate
buffered saline (PBS) with no calcium or magnesium (Sigma Aldrich, St.
Louis, MO). Lavage fluid was centrifuged to pellet peritoneal exudate cells
(PECs) for macrophage isolation.

iii.

Macrophage Isolation
Naive Mice – CD11b
Magnetic bead isolation products were purchased from Miltenyi Biotec
(San Diego, CA). PECs from each mouse were resuspended at 10 7 cells
in 80μL autoMACSTM running buffer, and incubated at room temperature
for 15min with CD11b beads. After washing, the cells were resuspended
in 500μL Running Buffer and passed through MS columns in a
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MiniMACSTM Separator magnet. After isolation the columns were washed
three times and eluted with 1mL running buffer and the isolated
macrophages counted. This macrophage enriched population was
manually quantified by hemocytometer with trypan blue exclusion method
to determine total macrophage numbers and cell viability.

CD11b beads were used to isolate the peritoneal macrophages from naive
mice, as CD11b forms part of the C3 complement receptor with CD18. In
mice it is strongly expressed on monocytes, macrophages and microglia.
There are lower levels of expression on granulocytes including
neutrophils, NK cells, CD5+ B cells and subsets of dendritic cells. F4/80 is
present on all mouse macrophages; however there is not a F4/80 bead
available. Preliminary experiments confirmed that >82% of CD11b+ cells
isolated from the peritoneum of naïve wild type mice were F4/80 + (Figure
3).

After Cecal Ligation and Puncture – F4/80
PECs were resuspended at 107 cells in 80μL PBS and incubated at 4°C
for 25min with F4/80 R-Phycoerythrin (PE) antibodies (eBiosciences).
After washing, the cells were resuspended in autoMACSTM running buffer
and incubated with anti-PE beads (Militenyi Biotec) for a further 25 min at
4°C. After a further wash, the cells were resuspended in 500μL running
buffer and passed through MS columns (Militenyi Biotec) in a MiniMACSTM
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Figure 3: CD11b isolation of Peritoneal Macrophages

A) The cell population from the peritoneum of naïve wild type mice was gated the
according to size (forward scatter – FSC) and granularity (side scatter – SSC). B)
Cells were stained to ascertain distinct populations (CD3+ – T cells, CD19+ - B
cells, CD 11b+ – myeloid cells, F4/80+ - macrophages). C) CD3-CD19- cells were
further gated to calculate the percentage of F4/80+ from all CD11b+ cells.
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Separator (Militenyi Biotec) magnet.

After isolation the columns were

washed three times and eluted with 1mL running buffer and the
macrophages counted. This macrophage enriched population was
manually quantified by hemocytometer with trypan blue exclusion method
to determine total macrophage numbers and cell viability.

Following CLP there is an influx of neutrophils and circulating
monocytes/macrophages into the peritoneum. These neutrophils are
CD11b+; therefore to prevent a significant population of neutrophils within
our macrophage samples, we performed the two-step isolation procedure.
The purity of the isolated macrophages was >80% as determined by flow
cytometry.

iv.

Lipopolysaccharide Stimulation
For most experiments the macrophages were suspended at 0.5x10 6/mL in
RPMI-1640 medium with 10% fetal bovine serum, 1% L-glutamine and 1%
antibiotic/antimycotic all from Sigma Aldrich (St. Louis, MO) and plated in
a 24 well plate at 0.5x106/1mL per well. Cells were rested overnight at
37°C in a humidified incubator with 5% CO2 prior to stimulation. Samples
were stimulated with lipopolysaccharide (LPS) 100ng/mL (E.Coli 011:B4;
Sigma Aldrich). After stimulation cells were incubated for the indicated
time periods. The culture media was removed and stored at -80°C for
cytokine quantification. Macrophages were allocated to either RNA
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isolation or lysed in 100μL of RIPA buffer (Sigma Aldrich) for protein
quantification and western blot.

The macrophages were rested overnight following isolation and prior to
stimulation.

We

have

previously

observed

activation

of

monocytes/macrophages by centrifugation, changing cytokine profile. In
order to see the response to a single LPS challenge, and avoid any
tolerance effects we allowed the cells to rest prior to LPS stimulation.

v.

RNA Isolation
Total RNA was isolated from the macrophages using mirVana miRNA
isolation kits (Ambion, Life technologies) following manufacturer’s
protocol. RNA concentrations were determined and RNA purity was
assessed using the NanoDrop 2000 (Thermo Scientific, Hudson, NH). All
sample fulfilled the quality criteria (A260/280 ratio between 1.8 and 2.1).

vi.

MiRNA and MessengerRNA Expression
MiRNA-21 expression was measured using Taqman® single miRNA
assays and Taqman MiRNA Reverse Transcription Kit for miRNA (Applied
Biosystems®, Life Technologies). U6 was used as a house keeping gene
miRNA for normalization.
For mRNA expression RNA was transcribed into complementary DNA
(cDNA) using High Capacity cDNA Reverse Transcription Kit for mRNA
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(Applied Biosystems®). Taqman single gene assays for PDCD4, Peli1,
SPRY1, SPRY2, and SPRY4. 18s was used as an internal control.
The StepOne Plus (Applied Biosystems®) was used to run the real time
Polymerase Chain Reaction (PCR) using Fast Advanced Master Mix and
the fast protocol (all products Life Technologies). StepOne Plus software
v2.1 (Applied Biosystems®) generated Cycle Threshold (CT) values which
were used to calculate fold changes using the ΔΔCT-method 95.

vii.

Cytokine Assays
TNF-α, IL-6 and IL-10 levels were measured in lavage media and culture
media

supernatants

using

enzyme-linked

immunosorbent

assays

(ELISAs). Murine Ready-Set-Go kits were purchased for all ELISAs from
e-Biosciences (San Diego, CA, USA) and then performed in 96-well plates
according to the manufacturer’s instructions. All samples were analyzed in
duplicate. Where necessary, samples were diluted in assay diluent to
achieve cytokine concentrations within the range of the standard curve.

viii.

Protein isolation
Protease and phosphatase inhibitors (Thermo Scientific) were added to
proteins in RIPA buffer and sonicated using a Sonifier 250 (Branson
Ultrasonics Danbury, CT). Protein quantification was determined by BCA
Assay (Thermo Scientific, Rockford, IL) against a standard curve on
Dynatech MR4000 using BioLinx 2.0 software.
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ix.

Western Blot
All products for Western Blots were purchased from Life Technologies
(Carlsbad, CA) unless otherwise specified and run according to
manufacturer’s protocols. 40μg of protein per sample was loaded into
wells of a Bolt 4-12% Bis-Tris Plus mini gel with 4x BoltTM LDS Sample
Buffer with 1:100 2-mercaptoethanol, and run in Bolt MES SDS Running
Buffer in a Bolt Mini Gel Tank on a Bio-Rad Power Pac 1000 (Hercules,
CA) at 165mV for 35-60 min with SeeBlue® Plus2 Prestained Standard.
Proteins were transferred onto Nitrocellulose membrane using iBlot® Gel
Transfer stacks and an iBlotTM transfer device.
Non-specific binding was blocked with 7% non-fat milk in TBS-T (9.68g
Tris base, 32g sodium chloride in 100mL ddH2O (pH adjusted to 7.6 with
concentrated hydrochloric acid), with 100μL Tween 20) for 1 hour at room
temperature. The membranes were incubated with rabbit anti-mouse
primary antibody overnight at 4°C.
All antibodies were purchased from Cell Signaling (Danvers, MA) unless
otherwise specified. All antibodies were suspended in 5% milk non-fat milk
made with TBS-T for 1-2 hours at room temperature or overnight at 4°C.
Antibody concentrations were as follows: Peli1 1:250 (Thermo Scientific),
PDCD4 1:500, SPRY1 1:200 (Santa Cruz Biotechnology, Inc, Dallas, TX),
SPRY2 1:1000, and SPRY4 1:500 (Thermo Scientific).
Following incubation with each antibody, membranes were washed three
times with TBS-T for 10 minutes. Subsequently the membranes were

30

incubated with rabbit anti-mouse primary antibody for housekeeping
protein β-actin (1:10,000) or glyceraldehyde 3-phosphate dehydrogenase
(GAPDH 1:10,000) and then with goat anti-rabbit secondary antibody
(1:5,000).
Pierce ECL Western Blotting Substrate (Thermo Scientific) was applied to
the membrane as per the manufacturer’s instructions. CL-XPosureTM Film
(Thermo Scientific) was used to expose the membrane for 15min. The
resultant image was developed, fixed, scanned and quantified using
ImageJ (National Institutes of Health, Bethesda, MD).

x.

MiRNA Transfection
To elucidate the anti-inflammatory effect of miRNA-21 on the macrophage
expression of cytokines, we transfected primary peritoneal macrophages
with mimics and antagomirs. MiRNA mimics are double-stranded RNAs
that are processed by Dicer and are incorporated into the RISC, acting in
the same way as endogenous miRNAs. The miRNA inhibitors in contrast
are single-stranded anti-sense RNAs that bind to the target miRNA which
leads to its degradation. The negative control has a hairpin structure like
the endogenous pre-miRNA, and is also processed by Dicer, but the
sequence is not complementary to any known gene, and therefore has no
active function with the cell.
For this experiment, the primary peritoneal macrophages from naïve wild
type C57BL/6 mice were suspended at 0.42x106 in RPMI-1640 medium
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with

10%

fetal

bovine

serum,

1%

L-glutamine

and

1%

antibiotic/antimycotic. Cells were immediately transfected. MirVana®
mimic, inhibitor and negative control to mmu-miR-21-5p (Life technologies,
Carlsbad, CA) were assembled with N-TER peptides (Sigma Aldrich) as
per manufacturer’s protocol.
0.25 x106 macrophages were incubated in a concentration of 120nM of
mimic, antagomir, or negative control for 24 hours in at 37°C with 5% CO 2
in cell suspension. After 24 hours, the samples were diluted with a further
600μL of media and stimulated with LPS 100ng/mL. Six or 24 hours after
LPS

stimulation,

the

culture

media

was

collected

for

cytokine

measurement and the macrophages processed for RNA isolation and
subsequent analysis of miRNA expression. An N of 1 was used for
macrophages from a single mouse used for mimic, antagomir, and
negative control.

xi.

Phosflow Pathway Analysis
Immortalized macrophages from miRNA-21+/+ and miRNA-21-/- mice were
resuspended at 0.5x106/mL RPMI-1640 medium with 10% fetal bovine
serum, 0.5% L-glutamine and 0.5% antibiotic/antimycotic. Cells in
suspension were rested overnight at 37°C in a humidified incubator with
5% CO2 prior to stimulation. After stimulation with LPS (100ng/mL), cells
were incubated for the indicated time periods. For baseline pathway
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activation determination, similarly cultured unstimulated miRNA-21+/+ and
miRNA-21-/- macrophages were used.
Following the indicated time, the cells were fixed immediately with
formaldehyde (3.2% pre-warmed), to maintain the phosphorylation status
of the pathways. After washing, cells were permeablized with chilled 100%
methanol. Cell samples were split for analysis of NF-κB or ERK activation.
Intracellular staining occurred in the dark for 1 hour with phospho-NF-κB
p65 or phospho-ERK AlexaFluor® 488 antibodies (Cell signal, Danvers,
MA). After staining, cells were washed and resuspended in 300μL FBSstain buffer (2% FBS in PBS, both Sigma Aldrich).
A FACS Calibur (BD Bioscience, San Jose, CA) was used to acquire the
samples. We counted 10,000 events for each sample. CellQuest Pro (BD
Bioscience) was used for analysis.

xii.

Peritonitis Models
Lipopolysaccharide Peritonitis
Male C57BL/6 miRNA-21+/+ and miRNA-21-/- mice aged 12-18 weeks were
weighed, single housed and fasted for 3 hours prior to intra-peritoneal
injection of 25mg/kg of E. coli LPS (E.Coli 055:B5; Sigma Aldrich). Surface
temperature, daily weight and survival were recorded for up to 5 days.
Mice were given food and water ad libitum. Preliminary experiments found
the optimal dose for a 50% survival in the wild type mice was 25mg/kg
with 3 hours of fasting prior to induction of peritonitis (Figure 4).
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Figure 4: Lipopolysaccharide Peritonitis Survival Curves

Multiple survival experiments were performed in wild type mice to find the optimal
dose for a survival of 40-60%. 25mg/kg with 3 hour fast was selected for final
experiments in miRNA-21+/+ and miRNA-21-/- mice.
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Cecal Ligation and Puncture Peritonitis
Male C57BL/6 miRNA-21+/+ and miRNA-21-/- mice aged 12-18 weeks were
weighed prior to undergoing cecal ligation and puncture. Briefly, under
isoflurane anesthesia, the abdomen was incised and, the cecum
exteriorized and ligated 1cm from the tip. A through and through puncture
was made with a 20G needle, and the cecum returned to the abdomen.
The peritoneal layer was closed with 3-0 Ticron and 50μL of 2% lignocaine
applied to the suture line. Skin was closed with 3-0 silk. Post-operatively
mice were given 600μL subcutaneous 0.9% saline and single housed.
Surface temperature, daily weight and survival were recorded for up to 5
days. Mice were given food and water ad libitum.

xiii.

Statistical Analysis
Data are shown as the mean ± standard error. Sigma Plot 13.0 (Systat
Software Inc, San Jose, CA) was used to perform Student’s t-test, ANOVA
and Linear Regression to determine statistical significance. A p value of
<0.05 was considered significant.
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CHAPTER IV
MIRNA-21 EXPRESSION IN PERITONEAL MACROPHAGES
Introduction
Recent studies have shown a role for miRNA-21 in the regulation of the TLR-4
pattern recognition receptor, which is present on macrophages amongst other
cells

42, 51

. TLR-4 activation leads to the initiation of the innate immune response

and release of pro- and anti-inflammatory cytokines. The expression of miRNA21 has been shown to increase in RAW264.7 cells following LPS stimulation

51

.

The pattern of expression in primary peritoneal macrophages has yet to be
ascertained. We propose that miRNA-21 expression in primary peritoneal
macrophages increases after LPS stimulation.

Results
MiRNA-21 Expression
MiRNA-21 expression increased in a linear fashion following LPS stimulation of
primary peritoneal macrophages to maximum fold change of 12 in the
observation period (R2=0.82, Figure 5).
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Figure 5: Peritoneal Macrophage MiRNA-21 Expression after
Lipopolysaccharide

A) Peritoneal macrophage miRNA-21 expression after lipopolysaccharide (LPS)
stimulation. N=8. B) Linear Regression R2 = 0.82, P = <0.001. Data are shown
Mean ± SEM.
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Secreted Cytokine Profile
The pro-inflammatory cytokines TNF-α and IL-6, were increased from 15min after
LPS stimulation (Figure 6). The levels of TNF-α peaked at 6 hours, were
somewhat decreased at 24 hours, but after that remained elevated. IL-6 peaked
at 12 hours and then plateaued. The anti-inflammatory cytokine IL-10 was also
increased from 15min after LPS stimulation, rising to a peak at 12 hours, and
then decreasing to 60% of maximum at the end of the observed period (Figure
7).
MiRNA-21 target mRNAs
The mRNA levels of the miRNA-21 target PDCD4 decreased sharply for the first
3 hours following LPS stimulation (Figure 8). This was followed by an increase
until 36 hours, and a subsequent decline, but always remained below baseline
levels.
Peli1 mRNA levels increased following LPS stimulation to a peak at 3 hours
(Figure 9). Levels returned to baseline at 24 hours and remained there for the
remainder of the observation period.
SPRY1 and 4 followed a pattern similar to Peli1, with an initial peak at 1 hour,
then returning to baseline around 24 and 6 hours respectively (Figure 10).
SPRY1 remained at baseline, while SPRY4 became down-regulated from 24
hours. SPRY2 has an initial increase and return to baseline within the first 3
hours, followed by a slower, greater increase in mRNA levels over 36 – 96 hours
which then declined.
38

Figure 6: Peritoneal Macrophage Pro-inflammatory cytokines after
Lipopolysaccharide

TNF-α and IL-6 concentrations from media of peritoneal macrophages after
lipopolysaccharide (LPS) stimulation. A) TNF-α and B) IL-6. N=8. Data are
shown Mean ± SEM.
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Figure 7: Peritoneal Macrophage Anti-inflammatory cytokine after
Lipopolysaccharide
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after

Figure 8: Peritoneal Macrophage PDCD4 mRNA expression after
Lipopolysaccharide

Peritoneal macrophage PDCD4 mRNA fold change after lipopolysaccharide
(LPS) stimulation. N=8. Data are shown Mean ± SEM.
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Figure 9: Peritoneal Macrophage Peli1 mRNA expression after
Lipopolysaccharide

Peritoneal macrophage Peli1 mRNA fold change after lipopolysaccharide (LPS)
stimulation peaked at 4 hours. N=8. Data are shown Mean ± SEM.
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Figure 10: Peritoneal Macrophage SPRY mRNA expression after
Lipopolysaccharide

Peritoneal macrophage mRNA fold change after lipopolysaccharide (LPS)
stimulation. A) SPRY 1 B) SPRY 2 C) SPRY 4. N=8. Data are shown Mean ±
SEM.
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Discussion
We found that there is a linear increase in the expression of miRNA-21 following
LPS stimulation in primary peritoneal macrophages. This observation is
consistent with previous data in a RAW264.7 mouse macrophage immortalized
cell line 51.
The observed rise in TNF-α, IL-6 and IL-10 following stimulation of our
macrophages-enriched population occurs, concurrently. More recent perceptions
of the interactions between pro- and anti-inflammatory responses to LPS
stimulation have noted that these responses occur simultaneously, though the
downstream effects maybe more delayed in the classical anti-inflammatory
response

25

. The initial decrease in the mRNA levels of PDCD4 and the steep

increase seen in Peli1, SPRY1 and 4 are due to the initial stimulation with LPS.
MiRNA-21 is induced steadily over time, and needs to be incorporated into the
RISC before these miRNAs can act to reduce mRNA levels or affect protein
translation. A delay in miRNA action is therefore expected. Together these data
do not give an obvious picture of miRNA-21 effects on target mRNA and
subsequent cytokine production. Confirmation of the regulatory effects of miRNA21 on TLR-4 signaling, requires modulation of miRNA-21 expression. The
macrophages were rested overnight following isolation and resuspension at the
required concentration. We have seen previously that centrifugation is able to
activate macrophages, changing cytokine profiles, therefore in order to see the
response to a single LPS challenge, and avoid any tolerance effects, we allowed
the cells to return to a ‘normal’ state prior to LPS stimulation.
44

Our observation period ended at 120 hours, as attempts at longer periods of
observation resulted in unviable primary peritoneal cells. The miRNA-21
expression was still increasing at that time point, and it would be advantageous
to understand for how long the miRNA-21 levels increase following LPS
stimulation, to ascertain the duration of miRNA-21 effect.
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CHAPTER V
MIRNA-21 HAS ANTI-INFLAMMATORY EFFECTS IN PERITONEAL
MACROPHAGES
Introduction
We have seen that miRNA-21 expression is increased in peritoneal
macrophages after LPS stimulation in vitro. The purpose of the next series of
experiments was to confirm the proposed anti-inflammatory role of miRNA-21 on
the production of TNF-α and IL-10. Based on our search of available literature,
we propose that miRNA-21 decreases TNF-α and increases IL-10 production by
a dual mechanism. Two proven targets of miRNA-21, PDCD4 and Peli1 are
positive regulators of the TLR -4 signaling pathway

36, 51, 61

. Inhibition of PDCD4

and Peli1 by miRNA-21 decreases the signaling of the TLR-4 pathway and
results in a decreased expression of TNF-α and its translation into protein, which
is then secreted. In contrast, the SPRY proteins are negative regulators of the
TLR-4 signaling pathway. Inhibition of SPRY expression leads to an increase in
ERK activation which leads to an increase in IL-10 expression and production.
Successful modulation of TNF-α and IL-10 secretion by manipulation of miRNA21 expression may have potential therapeutic applications. For this purpose we
modulated the expression of miRNA-21 in primary peritoneal macrophages with
mimics and antagomirs.
46

Results
Over-expression and Suppression of miRNA-21
Transfection of both mimics and antagomirs into primary peritoneal macrophages
was successful (Figure 11). The mimics achieved on average 1000- and 56-fold
increase in miRNA-21 levels at 6 and 24 hours respectively (P<0.001 and 0.029).
The antagomirs suppressed miRNA by 8-fold at 6 hours (p<0.001) after LPS and
37-fold after 24 hours though this was not statistically significant. Mimic and
antagomir miRNA-21 levels were compared to the negative control at that time
point.
Effect of miRNA-21on TNF-α at 6 and 24 hours
Manipulation of miRNA-21 expression led to changes in TNF-α concentration at
both 6 and 24 hours after LPS stimulation (Figure 12). Over-expression of
miRNA-21 resulted in a significant decrease in TNF-α at 6 hours (p=0.037) but
not 24 hours. Suppression of miRNA-21 significantly increased the TNF-α
produced at both 6 hours (p=0.037) and 24 hours (p=0.012).
Effect of miRNA-21on IL-10 at 6 and 24 hours
Modulation of miRNA-21 levels did not affect the levels of IL-10 at either time
point after LPS stimulation (Figure 13). At 24 hours there was a trend towards
increased IL-10 in the mimic-transfected macrophages; however the effects were
not consistent between mice.
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Figure 11: MiRNA-21 Expression after Transfection

Transfection with MiRNA-21 Mimic led to significant over expression of miRNA21 at both 6 and 24 hours after lipopolysaccharide (LPS) stimulation. The use of
antagomirs led suppressed miRNA-21 expression at both points, though only
statistically at 6 hours. N=9. Data are shown Mean ± SEM.*indicates p < 0.05 vs.
Negative Control.
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Figure 12: Effect of MiRNA-21 on TNF-α

Modulation of miRNA-21 expression showed the expected results. Suppression
of miRNA-21 significantly increased TNF-α. Over expression significantly
reduced TNF-α at 6 hours after lipopolysaccharide (LPS) stimulation but not after
24 hours. N=9. Data are shown Mean ± SEM. *indicates p < 0.05 vs. Negative
Control.
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Figure 13: Effect of
MiRNA-21
IL-10
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Modulation of miRNA-21 expression was not successful in modulating IL-10
secretion in primary peritoneal macrophages at either time point after
lipopolysaccharide (LPS) stimulation. N=9. Data are shown Mean ± SEM.
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Discussion
MiRNA-21 has anti-inflammatory effects on the primary peritoneal macrophage
response to LPS. MiRNA-21 decreases the activation of the TLR-4 pathway by
inhibiting PDCD4 and Peli1. These in turn decrease the activation of NF-κB and
the transcription of TNF-α, its translation into protein and subsequent release
from the macrophage in response to LPS. We proposed that miRNA-21 acts to
ameliorate the pro-inflammatory response by reducing levels of pro-inflammatory
cytokines such as TNF-α, though regulation of the TLR-4 MyD88 signaling
cascade, likely through the actions of proved targets PDCD4 and Pelino1.
MiRNA-21 also targets the Sprouty proteins which inhibit signaling in the ERK
arm of the MAPK signaling cascade, suggesting an increase in miRNA-21 levels
would also increase IL-10 production.
We have seen in previous experiments that miRNA-21 is induced in primary
peritoneal macrophages by stimulation with LPS (Figure 5)

51

. At 6 hours we

have a 1000 fold increase in miRNA-21 and only a 64 fold increase at 24 hours.
This is due to the normalization of miRNA-21 in the transfection samples.
MiRNA-21 levels in the negative control are physiologically lower at 6 hours
compared to those seen at 24 hours, and therefore provide a lower baseline for
comparison. Modulation of miRNA-21 expression is sufficient to significantly
change TNF-α expression in all cases except in the mimic-transfected cells at 24
hours. This may be due to competing endogenous RNAs (ceRNAs). Recent
literature has suggested a new component to miRNA regulation, the miRNA
sponge or ceRNAs

96-99

. These miRNA sponges contain multiple binding sites for
51

the miRNA of interest, and can act as effectively as artificial antisense
oligonucleotides

100

. Therefore the artificial up-regulation of miRNA-21 in

peritoneal macrophages by mimics could be counteracted by a known or
unknown mRNA target acting as a ceRNA. Each miRNA has hundreds of
potential targets based on gene sequencing, with only a few experimentally
verified. A miRNA sponge for miRNA-21 has not yet been identified, however
PTEN, a target of miRNA-21 in tumor cells has been implicated in other networks
101

.

In these experiments, miRNA-21 expression in peritoneal macrophages peaks at
a 10 fold up-regulation at 120 hours after LPS stimulation. Contrastingly, we see
a thousand fold up-regulation in the mimic-transfected macrophages, but this is
still insufficient to elicit a significant change in the IL-10 production. There is no
difference in IL-10 concentrations at either time point, though there is a trend
towards higher levels in the mimic-transfected macrophages at 24 hours. We
proposed that the effects of miRNA-21 on IL-10 production are regulated through
the ERK signaling cascade. MiRNA-21 inhibits the Sprouty proteins, which in
turn inhibit the ERK cascade. There are 4 Sprouty isoforms, all of which are
theoretical targets of miRNA-21. Higher levels of miRNA-21 may be required to
sufficiently inhibit the protein levels, in order to see a change in IL-10 production,
even at 24 hours. We have shown that successful transfection of peritoneal
macrophages results in changes in TNF-α concentrations, which are directly
linked to survival in sepsis.
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CHAPTER VI
MIRNA-21 HAS ANTI-INFLAMMATORY EFFECTS IN BONE MARROW
MACROPHAGES
Introduction
In previous experiments we have seen that successful inhibition of miRNA-21
with antagomir-transfected primary peritoneal macrophages resulted in lower
levels of TNF-α production. The purpose of the next experiment was to confirm
these results in a macrophage cell line utilizing miRNA-21+/+ and miRNA-21-/bone marrow derived macrophage cell lines. Inhibition of endogenous miRNAs
with transfection is often incomplete, as transfection efficiency can vary from cell
to cell within a treated sample. However, the use of an immortalized cell line from
transgenic mice will likely yield novel data as to the importance of the gene in
regulation of the TLR-4 signaling pathway.
We propose that using the miRNA-21-/- bone marrow derived macrophage cell
line will add important additional data regarding miRNA-21 regulation of the
pattern of cytokine production following LPS stimulation.
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Results
Effect of miRNA-21 knockdown on TNF-α
MiRNA-21 knockdown was confirmed by PCR. Knockdown of miRNA-21
expression led to changes in TNF-α concentration from 6 hours after LPS
stimulation (Figure 14). TNF-α concentration was significantly higher at 6 and 24
hours (p<0.05), and trending towards significance at 48 hours (p=0.059) in the
miRNA-21-/- macrophages.
Effect of miRNA-21 knockdown on IL-6
IL-6 concentration also changed after LPS stimulation in miRNA-21-/macrophages (Figure 15). IL-6 was significantly higher at 24 and 48 hours
(p<0.05) in the miRNA-21-/- macrophages.
Effect of miRNA-21 knockdown on IL-10
Knockdown of miRNA-21 expression led to changes in IL-10 concentration at
early time points after LPS stimulation (Figure 16). The concentration of IL-10 in
the cell culture media was significantly lower from 1 hour after LPS in the miRNA21-/- macrophages and did not reach miRNA-21+/+ levels until 24 hours (p<0.05).
Effect of miRNA-21 on target proteins
PDCD4 protein abundance was similar in both miRNA-21+/+ and miRNA-21-/macrophages both at baseline before LPS stimulation and 24 hours afterwards
(Figure 17). No difference was detected in Peli1 protein abundance at 24 hours
after LPS stimulation (Figure 18). SPRY 1 and 2 protein levels were not different
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Figure 14: TNF-α in Bone Marrow derived Macrophages

Knockdown of miRNA-21 led to significant increase in TNF-α levels following
lipopolysaccharide (LPS) stimulation. N=8. Data are shown Mean ± SEM.
*indicates p < 0.05
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Figure 15: IL-6 in Bone Marrow derived Macrophages

Knockdown of miRNA-21 led to significant increase in IL-6 levels following
lipopolysaccharide (LPS) stimulation. N=8. Data are shown Mean ± SEM.
*indicates p < 0.05.
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Figure 16: IL-10 in Bone Marrow derived Macrophages

Knockdown of miRNA-21 led to significant decrease in IL-10 levels at early time
points following lipopolysaccharide (LPS) stimulation. N=8. Data are shown Mean
± SEM. *indicates p < 0.05
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Figure 17: PDCD4 in Bone Marrow derived Macrophages

Knockdown of miRNA-21 did not lead to a significant change in PDCD4 protein
at A) Baseline or B) 24 hours following lipopolysaccharide (LPS) stimulation. N=3
Data are shown Mean ± SEM.
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Relative Abundance

Figure 18: Peli1 in Bone Marrow
Macrophages
24derived
hr Peli1
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Knockdown of miRNA-21 did not lead to a significant change in Peli1 protein at
24 hours following lipopolysaccharide (LPS) stimulation. N=4. Data are shown
Mean ± SEM.
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between miRNA-21+/+ and miRNA-21-/- macrophages 24 hours after LPS
stimulation (Figure 19). SPRY 4 protein was not detectable in either cell line after
24 hours with LPS.

Discussion
Knockdown of miRNA-21 in the bone marrow derived macrophage cell line
confirmed

the

anti-inflammatory effects of

miRNA-21

seen

on

TNF-α

concentrations in the antagomir-transfected primary peritoneal macrophages.
Concentrations of another pro-inflammatory cytokine IL-6, were also significantly
higher after LPS stimulation in miRNA-21-/- compared to miRNA-21+/+
macrophages, though at later time points. From our data in primary peritoneal
cells, we observed that Peli1 mRNA expression is induced by LPS stimulation, at
a faster rate than miRNA-21. The time taken for miRNA-21 to be transcribed,
processed, incorporated into the RISC and to act on Peli1 mRNA may be the
delay observed between LPS stimulation and the change in TNF-α production
seen between miRNA-21+/+ and miRNA-21-/- macrophages.
In the transfected primary peritoneal macrophages we were surprised not to see
any changes in IL-10 concentration with either the mimics or antagomirs. The
miRNA-21-/- macrophages had significantly lower levels of IL-10 at early time
points after LPS stimulation. MiRNAs act by inhibiting protein translation;
therefore if a miRNA is constitutively turned off, as in knockout cells, we propose
that there will be higher baseline levels of that protein expressed within the cell.
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Figure 19: SPRY 1 and 2 in Bone Marrow derived Macrophages

`
Knockdown of miRNA-21 did not lead to a detectable change in A) SPRY 1 or B)
SPRY 2 levels at 24 hours following lipopolysaccharide (LPS) stimulation. N=4
Data are shown Mean ± SEM.
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Sprouty proteins inhibit the ERK signaling cascade, which in turn leads to a
reduced IL-10 expression; this correlates with the lower levels of IL-10 seen in
the miRNA-21-/- macrophages, where we would expect to see higher levels of
Sprouty.
The observed changes in cytokine production between miRNA-21+/+ and miRNA21-/- cells leads to an expectation that we will detect associated differences in the
miRNA-21 target proteins, with higher levels present in the miRNA-21-/- cell lines.
There was a trend towards higher levels of PDCD4 at baseline (no LPS) in the
miRNA-21-/- cell line (Figure 17A). However, at 24 hours no difference was
detectable.
PDCD4 protein has been shown to be reduced following LPS stimulation at 24
hours in RAW264.7 cells, mouse bone marrow derived macrophages

and

human peripheral blood monocytes, with the same dose as used in these
experiments 51. Knockdown of PDCD4 protein levels was shown with pro-miRNA21 in RAW264.7 cells with and without LPS stimulation. This is contrary to what
we saw in our results. This may be due to differences in cell culture
concentrations, as we increased our cell concentration in order to increase the
protein yield for western blot samples. The difference in protein levels may be
more subtle than we are able to detect.
We did not discern any significant difference between the levels of Peli1, SPRY
1, 2 or 4 at 24 hours after LPS stimulation. Peli1-/- mice have been used to
ascertain the impact of Peli1 on LPS signaling through TLR-4, however the link
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between miRNA-21 and Peli1 has only been studied in liver regeneration, and
there was no causal time delay between miRNA-21 up-regulation and the
changes in Peli1 mRNA

36, 61

. There are no data with which to compare our Peli1

protein findings in macrophages after LPS.
SPRY proteins have not previously been directly linked to TLR-4 signaling,
though they have been shown to inhibit p38 in the MAPK pathway of interferon
receptor signaling in mouse embryonic fibroblasts

102

. The experimental

verification of SPRY proteins as targets of miRNA-21 have occurred in other nonmacrophage cell types

73, 92

. SPRY proteins are induced by ERK activation

66

.

The similarities between the abundance in both miRNA-21+/+ and miRNA-21-/macrophage cell lines may be because the SPRY proteins do not have an
important role to play in TLR-4 signaling. Further experiments using either
silencing RNA (siRNA) or SPRY protein knockouts will add data to inform
whether SPRY proteins modulate TLR-4 signaling.
We have corroborated our previous data that miRNA-21 changes the
macrophage cytokine profile in response to LPS stimulation. We believe that he
likely candidate as the most important miRNA-21 target protein in regulating
TLR-4 signaling from our data is PDCD4.
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CHAPTER VII
MIRNA-21 AFFECTS NF-ΚB AND ERK SIGNALING IN BONE MARROW
MACROPHAGES
Introduction
Intracellular signaling pathways allow cells to respond to external stimuli. Pattern
recognition receptors on both the cell surface and within the cell identify
pathogen associated molecular proteins to activate an appropriate immune
response. Two important pathways in macrophages are the NF-κB and MAPK
pathways. Activation of these pathways results in the release of cytokines to
orchestrate the immune response to the invading pathogen. Cytokines act both
locally and systemically. Pro-inflammatory cytokine release leads to the local
recruitment of immune cells from the vasculature, and also the development of
the systemic acute phase response and fever. These effects combine to enhance
host defense against such pathogens and directly combat the infection.
Manipulation of these pathways therefore has the potential to affect the way
macrophages respond to pathogens. MiRNA-21 has been shown to inhibit the
production of PDCD4 and Peli1 proteins which both affect the TLR-4 signaling
cascade

51, 61

. Knockout of Peli1 affects NF-κB activation following LPS

64

stimulation

36

. The ERK arm of the MAPK pathway in macrophages has been

previously linked to IL-10 production
inhibit the ERK signaling pathway

88

. SPRY proteins have been shown to

66, 69, 103

. SPRY proteins are targets of miRNA-

21 73, 92.
We propose that knockout of miRNA-21 will lead to increased NF-κB activation
which would explain the higher levels of TNF-α seen after LPS stimulation in
these cells. We also hypothesize that decreased ERK activation in the miRNA21-/- macrophages may account for the lower levels of IL-10 seen at the early
time points.

Results
Activation of the NF-κB pathway
There was a maximal increase in the levels of NF-κB 10 minutes after LPS
stimulation (Figure 20). This elevation continued throughout the observed 2 hour
period. There was no difference in activation between miRNA-21+/+ and miRNA21-/- bone marrow derived macrophages. Where comparing relative activation,
the cells were more similar.
Activation of the ERK pathway
The pattern of ERK phosphorylation after LPS stimulation is unclear (Figure 21).
The relative activation shows a higher peak in the miRNA-21+/+macrophages
than miRNA-21-/- cells.
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Figure 20: NF-κB Activation after Lipopolysaccharide in Bone Marrow
derived Macrophages

Activation of NF-κB p65 subunit was not different between miRNA-21+/+ and
miRNA-21-/- bone marrow derived macrophage cell lines after lipopolysaccharide
(LPS) stimulation. A) Mean channel fluorescence B) Relative Activation. N=4.
Data are shown Mean ± SEM.

66

Figure 21: ERK Activation after Lipopolysaccharide in Bone Marrow
derived Macrophages

Activation of ERK was not significantly different between miRNA-21+/+ and
miRNA-21-/- bone marrow derived macrophage cell lines after lipopolysaccharide
(LPS) stimulation. A) Mean channel fluorescence B) Relative Activation. N=4.
Data are shown Mean ± SEM.
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Discussion
Changes in TNF-α production have been shown to be associated with NF-κB
activation

77, 78

. However, we were unable to show an association in this

experiment between the production of miRNA-21 and the activation of NF-κB
despite changes in TNF-α between the cell lines (Figure 14). We did show the
speed at which NF-κB is activated following LPS stimulation, and that it continues
for at least 2 hours (Figure 20). There are 5 subunits of NF-κB, and we only
studied activation of p65, it may be that another subunit is important for miRNA21 related effects, as the NF-κB p50 subunit is the key regulator in LPS-tolerant
transition to a M2 polarized phenotype in macrophages

104

.

The pattern of ERK activation seen in our bone marrow macrophage cell lines is
unclear. The relative activation shows a higher peak in the miRNA-21+/+
macrophages which has been noted to correlate with higher IL-10 levels 79, 88.
The absence of a difference seen between these cell lines maybe related to the
cell type. These are immortalized bone marrow derived macrophages that are
grown in cell culture and split before they become confluent. They are not
peritoneal macrophages that have been nurtured in an organic environment, and
the long-term culture may have affected the signaling pathways.
There is also a question of how closely bone marrow derived macrophages are
related to peritoneal macrophages. Although a recent study shows that peritoneal
macrophages have increased expression of proteases and acute phase factors,
with down regulation of the production of several chemokines compared to blood
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monocytes. There are other studies that show that the monocytes present in
blood migrate to the tissues including the peritoneum to become resident
macrophages

105, 106

. Further work has been done by Ghosn who identified 2

subgroups of CD11b+F4/80+ macrophages found within the peritoneal cavity

107

.

These have been termed large and small peritoneal macrophages due to size
distinctions. Large peritoneal macrophages make up 90% of the peritoneal
macrophage population in the naive abdomen and have higher levels of CD11b
and F4/80. Both are able to phagocytose bacteria. Two days after LPS
stimulation, the small macrophages become the dominate cell type, and cell
marker data suggests that they have differentiated from blood monocytes.
Despite the absence of evidence seen in this experiment, we can extrapolate that
miRNA-21 affects the TLR-4 signaling pathway, though the changes to NF-κB
and ERK activation may be too subtle for us to detect with this technique.
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CHAPTER VIII
INFLUENCE OF MIRNA-21 ON SURVIVAL IN
LIPOPOLYSACCHARIDE PERITONITIS
Introduction
Despite having a tried and tested treatment for peritonitis and the ability to predict
those with a higher risk of morbidity and mortality with various scoring systems,
we still do not know why some patients are unable to contain and eliminate an
infection, resulting in a persistence of bacteria in the peritoneum. Some
investigators have theorized that this is due to a failure of the host immune
response to clear the infection, and that augmentation or modulation of the
immune response may benefit bacterial clearance in these patients. Several
immune-modulators have been tested in clinical trials following success in a lab
environment, however without success in a clinical setting

16, 17

.

Recent studies have shown that mice with knockdown of PDCD4 and Pelino 1
genes have a greater survival to LPS peritonitis than their wild type counterparts
36, 51

. These proteins affect downstream signaling of TLR-4 through MyD88 and

NF-κB. MiRNA-21 has been shown to target both these proteins and is itself
induced after LPS administration in macrophages

51

. Based on these data we

predicted that miRNA-21 knockout mice would have a decrease survival
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to induced peritonitis. MiRNA-21 production is stimulated through TLR-4
signaling, so we used a model of intra-peritoneal LPS to induce peritonitis. LPS is
considered to be an important inducer of the septic response and intra-peritoneal
LPS is more likely to induce a hyperdynamic cardiovascular response than
intravenous (IV) administration and is thus a better model for the human
condition 16.

Results
Lipopolysaccharide Peritonitis
Surface temperature and weight decreased in all mice following induction of
peritonitis with LPS (Figures 22 and 23). Failure to regain temperature and
weight was predictive of subsequent death. The miRNA-21+/+ mice began to die
after 24 hours, the miRNA-21-/- mice after 40 hours (Figure 24). Significantly,
more miRNA-21-/- mice died compared with miRNA-21+/+ mice (p=0.002).

Discussion
This study was performed in a constant room temperature at 28°C, and all mice
had reduced their body temperature following intra-peritoneal administration of
LPS. This is typical of the response seen to induced sepsis in mice; however in
patients the induction of fever is seen. Recent data suggest that the surroundings
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Figure 22: Mouse Surface Temperatures after Lipopolysaccharide
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miRNA-21-/-mice were included in this figure. Survivors N=5, Deaths N=21. Data
are shown Mean ± SEM.
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Figure 23: Mouse Weight after Lipopolysaccharide Peritonitis

Weight decreased in all mice following intra-peritoneal administration of
lipopolysaccharide (LPS). The mice that died during the observation period did
not recover the weight lost. Mice that survived were regaining weight by the
termination of the study. A) MiRNA-21+/+ N=17, B) miRNA-21-/- N=9.
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Figure 24: Survival after Lipopolysaccharide Peritonitis

MiRNA-21 confers a significant survival benefit in response to 25mg/kg
lipopolysaccharide (LPS) peritonitis. MiRNA-21+/+ N=17, miRNA-21-/- N=9.
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in which mice are kept impacts the temperature response

108, 109

. Below a room

temperature of 30°C, mice are already working to maintain body temperature,
and are thus unable to generate enough heat to produce the fever response
usually associated with sepsis. This leads to the hypothermic response seen and
thus subsequent experiments should ideally be performed in a room at 30°C. All
mice lost weight following induction of peritonitis. This is indicative of the
increased metabolic demand placed on the body. Only animals that survived the
observation period gained weight following peritonitis (Figure 23). We have used
weight loss as a predictor of mortality in previous models of peritonitis

110

.

The knockdown of miRNA-21 confers a survival benefit in LPS peritonitis (Figure
24). Mortality due to LPS is associated with cardiac dysfunction related to
intravascular inflammation and thrombosis in microvasculature function

111

. This

impairment in microcirculation leads to multiple organ failure, disseminated
intravascular coagulation (DIC) and death

112, 113

. Inhibition of platelet adhesion

through GPIb-IX binding decreases the mortality of LPS challenged mice

114

.

TNF-α activates the common pathway of coagulation, leading to thrombotic
consequences

115

. The cardiopulmonary dysfunction seen in animal models of

sepsis can be attenuated by monoclonal TNF-α antibody 116.
TNF-α is an important cytokine mediator of sepsis, essential to the generation of
the innate immune response to infection. It is found in the circulation following
administration of LPS, and when given directly mimics many of the physiological
and laboratory features following intravenous LPS

117

. However plasma levels of

TNF-α following endotoxin are an order of magnitude higher than circulating
75

levels in sepsis

16, 118-120

. If one of the downstream effects of miRNA-21 is to

decrease circulating TNF-α levels, this correlates with the fact that the higher
levels of TNF-α seen following LPS peritonitis are attenuated and therefore
survival is improved in miRNA-21+/+ mice compared to miRNA-21-/- mice. In
miRNA-21-/- mice there would be no amelioration of the already high TNF-α levels
seen after administration of LPS, and therefore these mice have a higher
mortality. TNF-α blockade alone is not sufficicent to reduce mortality following
LPS peritonitis in animals or when administered in clinical trials, and indeed
higher doses of TNF-α blockade increases mortality

120, 121

. IL-10 had been

shown to reduce mortality in a lethal model of LPS peritonitis

87

. These data

suggests that it is not TNF-α alone, but a combination of factors by which
miRNA-21 reduced mortality in our experiment.
Our initial experiment focused on the TLR-4 pathway by inducing peritonitis with
a specific ligand. However, LPS is a single protein from the outer membrane of a
single organism (E.coli), given at a single point in time, which signals through a
single pattern recognition receptor and triggers the innate immune response
through the TLR-4 pathway. In reality, secondary peritoneal infection is
polymicrobial, with entry of multiple enteric bacteria into the peritoneum, resulting
in the continuous migration of bacteria into the vascular space, mainly through
the subdiaphragmatic lymphatics. This results in multiple PAMPs and DAMPs
being recognized by PRRs and the activation of multiple signaling pathways.
Cecal Ligation and Puncture is a more representative model of peritonitis that will
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better assess if this promising effect of miRNA-21 on mortality in peritonitis would
be beneficial in a patient population

90

.
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CHAPTER IX
INFLUENCE OF MIRNA-21 ON SURVIVAL IN CECAL LIGATION
AND PUNCTURE PERITONITIS
Introduction
Our previous experiments have shown that expression of miRNA-21 confers a
survival benefit in a lipopolysaccharide model of peritonitis. Previous studies of
immune modulators in sepsis that have used LPS peritonitis as an experimental
model, that showed a difference in outcome in animal studies, have not
translated into differences in clinical studies

122

. This is because LPS induced

inflammation is not an accurate mimic of the human disease state. LPS is an
outer membrane protein from a gram negative bacterium (often E. coli) that
signals through a single pattern recognition receptor (TLR-4) and triggers the
innate immune response through a single pathway. It is also given as a single
bolus, whereas in most human infections bacteria are released and multiply in
the bloodstream of the host more slowly over time. For these reasons we felt it
was important to assess the influence of miRNA-21 on survival in a more
clinically relevant model of peritonitis, CLP. The CLP model combines the entry
of enteric bacteria into the peritoneum together with an ischemic focus and is
thus closer to peritonitis as seen in patients. If miRNA-21 is to be a potential
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immune modulator in a clinical setting, then it will need to show a difference in
more clinically relevant animal models of peritonitis such as CLP. We propose
that miRNA-21 will show a survival difference between the miRNA-21+/+ and
miRNA-21-/- mice following CLP.

Results
Surface temperature and weight decreased in all mice following induction of
peritonitis with CLP (Figure 25). Surface temperature improved in the mice that
survived, though never recovered to baseline levels during the observation
period. There was no difference in survival following induction of peritonitis with
CLP between the miRNA-21+/+ and miRNA-21-/- mice (Figure 26).

Discussion
MiRNA-21 confers a survival benefit in LPS peritonitis but not after CLP. This is a
result that has also been seen with other potential immune modulators 120. LPS is
a ligand for TLR-4, and thus triggers the immune response through this single
pathway. As miRNA-21 is induced by and acts on the TLR-4 pathway, it is
therefore logical that we see a difference in survival between miRNA-21+/+ and
miRNA-21-/- mice after LPS induced peritonitis.
In contrast CLP is a combination of ischemia, foreign body reaction and
polymicrobial infection from the enteric bacteria of the gut. This leads to a live
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Figure 25: Surface Temperature and Weight in mice after Cecal Ligation
and Puncture

Surface temperature and weight decreased in all mice following induction of
peritonitis with 20G cecal ligation and puncture (CLP). The mice that died during
the observation period had lower temperatures than those that survived. MiRNA21+/+ and miRNA-21-/-mice were included in this figure. Survivors N=8, Deaths
N=12.
80

Survival Analysis

Figure 26: Survival after 20G Cecal Ligation and Puncture
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MiRNA-21 does not convey a survival benefit in response to peritonitis by 20G
cecal ligation and puncture (CLP). N=10.
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bacterial infection with a multitude of exogenous mediators such as microbial
DNA, lipoteichoic acid, peptidoglycan and other cell wall components which
signal through multiple pathways such as TLR-2, TLR-6, TLR-9, NOD-like
receptors as well as TLR-4 to initiate the immune response. LPS peritonitis is
induced by an intra-peritoneal bolus, which induces an initial response that does
not need to escalate over time. The infection seen after CLP involves cecal
necrosis, with multiplying species of bacteria within the peritoneum and eventual
bacteremia over time. The infection becomes walled off in an abscess cavity over
the first 72 hours, and is eventually extruded through the abdominal wall if the
animal survives

123

. This ongoing contamination in CLP requires a more complex

continued immune response.
TNF-α is an important cytokine mediator of sepsis, essential to the generation of
the innate immune response to infection. It is found in the circulation following
administration of LPS, and when given directly mimics many of the physiological
117

and laboratory features following intravenous LPS
TNF-α has a positive correlation with mortality

. The level of circulating

110, 124

. Reducing the levels of

circulating TNF-α using anti-TNF-α monoclonal antibodies in experimental animal
models of sepsis using LPS and gram negative bacteria, has had some success
in decreasing mortally across a range of species

124-126

. Animals unable to

produce TNF-α in response to infection did worse than endotoxin sensitive mice,
demonstrating that a proportional immune response is required

127

. However

plasma levels of TNF-α following LPS administration are an order of magnitude
higher than circulating levels in polymicrobial sepsis
82

16, 118-120, 128

. TNF-α blockade

has been shown to be ineffective or detrimental in mice following induction of
peritonitis with CLP

119, 120

. This is consistent with clinical trials of TNF-α

antagonists that did not show an improved survival, and at higher doses
increased mortality 17, 129, 130.
MiRNA-21 decreases circulating TNF-α, and therefore will have more effect on
the higher levels of TNF-α seen following LPS peritonitis. The attenuation of
TNF-α that occurs in miRNA-21+/+ mice may be related to the subsequent
improved survival. MiRNA-21-/- mice do not have the same amelioration of the
high TNF-α concentration seen after administration of LPS. In CLP there are
lower levels of circulating TNF-α, and therefore the effects of miRNA-21 on TNFα levels will be reduced, and potentially insufficient to have an effect on mortality.
TNF-α is not the only factor important in the pathophysiology of sepsis, as a
reduction in TNF-α has no effect on neutrophil infiltration of the lung, as a major
cause of mortality following CLP

120

. These data demonstrate that TNF-α is not

the mediator of lethality in polymicrobial peritonitis, yet has a role to play with a
multitude of other mediators.
TLR-4 signaling produces multiple cytokines, both pro- and anti-inflammatory in
response to stimulation with LPS, both through the NF-κB and ERK pathways.
Following CLP, TLR-4 gene expression and protein abundance was increased in
liver and lung compared with controls and correlates with mortality

131

.

Inflammation, tissue damage and lethality are diminished in the absence of TLR4 signaling 132.
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With these data TLR-4 antagonists have been developed, which competitively
bind to TLR-4, preventing LPS interaction, and have been shown to decrease
pro-inflammatory cytokine release and inhibit the development of inflammation
133-135

. However the ACCESS randomized clinical trial of Eritoran®, an antagonist

of the MD2-TLR-4 complex, did not show any significant difference when trialed
in patients with severe sepsis

136

. In contrast M62812, a molecule that inhibits

TLR-4 signal transduction, has shown an increased survival in both Dgalactosamine-sensitized endotoxin shock model and 18G CLP model at 24
hours

134

. However increased survival over a longer time period was not

reported.
One group has looked further into the role of TLR-4 on different cells types.
Using a 22G CLP model a global TLR-4 deletion and myeloid (neutrophil and
macrophages) TLR-4 deletion had 100% mortality compared to 40% in the wild
type mice after 7 days

137

. Bacterial clearance from the circulation and

peritoneum in these mice was significantly impaired compared to wild type. The
failure to clear bacteria correlated with an increase in inflammatory markers,
even in the absence of TLR-4 on myeloid cells. Efficiency of bacterial clearance
in this model determines survival and the magnitude of the immune response,
which are in turn determined by LPS recognition by TLR-4 on macrophages.
TLR-4 on macrophages is therefore important for the stimulation of bacterial
phagocytosis in polymicrobial sepsis.
The cause of mortality related to LPS peritonitis differs from that seen after CLP
90

. LPS mortality is associated with cardiac dysfunction and related to
84

111

intravascular inflammation and thrombosis in the microvasculature

. This

impairment in the microcirculation leads to multiple organ failure, disseminated
intravascular coagulation (DIC) and death

112, 113

. TNF-α activates the common
115

pathway of coagulation, leading to thrombotic consequences

. The

cardiopulmonary dysfunction seen in animal models of sepsis can be attenuated
by monoclonal TNF-α antibody

116

.Suppression of LPS-induced up-regulation of

inflammatory cytokines, by TLR-4 signal transduction inhibitor M62812, also led
to suppression of pro-coagulant activity in peripheral mononuclear cells

134

. Up-

regulation of pro-coagulant activity in leukocytes and down-regulation of
anticoagulant activity in endothelial cells leads to microthrombosis in several
organs, leading to multiple organ failure. Inhibition of platelet adhesion through
GPIb-IX binding also decreases the mortality of LPS challenged mice

114

.

After CLP animals develop an initial hyper dynamic cardiovascular response,
similar to that seen in patients with increased cardiac output and decreased
systemic vascular resistance

90

. This develops into systemic bacteraemic

infection and sepsis, which progressively become cardiovascular collapse due to
septic shock and death days after the initial insult, similar to the condition seen in
peritonitis patients who die from multiple organ failure days after the onset of
infection. CLP using a 16G double puncture technique leads to a significant
cardiac dysfunction, shown by a decreased ejection fraction by 25.7%
is also a component of lung injury due to neutrophil infiltration

138

. There

139

.

Innate

immunity also participates in polymicrobial sepsis-induced acute kidney injury
through the MyD88 pathway, by leading to an increased migration of neutrophils
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to the kidney, increased production of pro-inflammatory cytokines, vascular
permeability, hypoxia and apoptosis of tubular cells

140

. TLR-4-/- mice had

decreased renal injury at 24 hours with a diminished systemic cytokine response
following 23G CLP
type mice

140

. CLP and LPS both enhance thrombotic occlusion in wild-

141

. LPS, but not CLP, increased plasma VWF antigen relative to

controls. CLP alternatively enhanced thrombosis in TLR-4 and VWF-deficient
strains. As miRNA-21 has not been shown to have a regulatory role in other
immune signaling pathways, the redundancy present from the multiple pathways
stimulated in CLP may minimize the effects of miRNA-21 in this peritonitis model.
These experiments used whole body knockout mice to model an absence of
miRNA-21. As these mice survived to 12 weeks and beyond we know that
miRNA-21 is not essential for animal survival. We do not know what adaptions
have occurred within the mouse, specifically in the immune system in order to
compensate for the missing miRNA-21, though there were no significant changes
in hemopoetic cells populations seen in the blood, peritoneum or bone marrow
on flow cytometry (data not shown). Creation of a model that has inducible
knockdown of miRNA-21 in only the macrophage population would be ideal to
truly see the effect of macrophage miRNA-21 in these models of peritonitis. A
closer model would be to transplant bone marrow from miRNA-21-/- mice into
miRNA-21+/+ mice, as then the subsequent miRNA-21 knockdown would be
confined to only the hematological cells. However, this would still allow for
adaptations to occur within the immune system.
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Although mortality is a definitive end-point most patients survive an episode of
peritonitis with modern therapy. MiRNA-21 may still ameliorate the severity of
infection without affecting mortality rate. In patients, decreasing the need for
organ support and intensive care would be a significant step forward in improving
the patient experience, decreasing length of stay and subsequent health care
costs.
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CHAPTER X
MIRNA-21 EXPRESSION IN PERITONEAL MACROPHAGES
FOLLOWING CECAL LIGATION AND PUNCTURE PERITONITIS
Introduction
Cecal ligation and puncture is among the most representative models of human
peritonitis. Multiple pathways are stimulated by the polymicrobial infection from
enteric bacteria. These pathways stimulate cell activation and trigger secondary
cascades, resulting in cytokine and chemokine release. MiRNA-21 regulates the
TLR-4 signaling cascade, one of many that are activated by polymicrobial intraabdominal infection. We saw no difference in survival between miRNA-21+/+ and
miRNA-21-/- mice following 20G CLP. We propose, based on these data, that
despite the absence of a difference in survival, we will see a difference in the
levels of miRNA-21 in the macrophage population and the intra-peritoneal
cytokine profile.
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Results
MiRNA-21 Expression
MiRNA-21-/- was confirmed by RT-qPCR. In miRNA-21+/+ mice miRNA-21
expression was initially down-regulated in the F4/80+ peritoneal macrophage
population at 6 and 24 hours following CLP (Figure 27). At 48 hours the
expression was up-regulated by 500 fold but with a wide range of variation.
Cell Populations
MiRNA-21+/+ and miRNA-21-/- mice had no difference in the number of peritoneal
exudate cells harvested from the peritoneum at 6, 24 or 48 hours after 20G CLP
(Figure 28). The number of macrophages isolated was not different between the
groups, nor the macrophage population as a percentage of the total number of
PEC cells (Figure 29).
Effect of miRNA-21on Peritoneal Cytokines levels
Following 20G CLP TNF-α was higher in the peritoneal lavage media from
miRNA-21+/+ mice at 6 hours (p=0.009), but no different at 24 and 48 hours
(Figure 30). IL-6 concentrations peaked at 6 hours after CLP, but was no
different in the peritoneum between miRNA-21+/+ and miRNA-21-/- mice (Figure
31). Similarly IL-10 levels were maximally elevated at 6 hours, with the same
pattern occurring in both miRNA-21+/+ and miRNA-21-/- mice (Figure 32).
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Figure 27: Peritoneal Macrophage MiRNA-21 Expression after Cecal
Ligation and Puncture

Peritoneal macrophage miRNA-21 expression after 20G cecal ligation and
puncture (CLP). N=7. Data are shown Mean ± SEM.
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Figure 28: Peritoneal Exudate Cell counts after Cecal Ligation and Puncture

There is no difference in the number of peritoneal exudate cells between miRNA21+/+ and miRNA-21-/-mice following cecal ligation and puncture (CLP). N=7-8.
Data are shown Mean ± SEM.
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Figure 29: Peritoneal Macrophages after Cecal Ligation and Puncture

A) There is no difference in the number of peritoneal macrophages between
miRNA-21+/+ and miRNA-21-/-mice, not B) the percentage of the total peritoneal
population following cecal ligation and puncture (CLP). N=7-8. Data are shown
Mean ± SEM.
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Figure 30: Peritoneal TNF-α after Cecal Ligation and Puncture

There is no difference in the peritoneal TNF-α levels between miRNA-21+/+ and
miRNA-21-/-mice following cecal ligation and puncture (CLP). N=7-8. Data are
shown Mean ± SEM.
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Figure 31: Peritoneal IL-6 after Cecal Ligation and Puncture
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There is no difference in the peritoneal IL-6 between miRNA-21+/+ and miRNA21-/-mice following cecal ligation and puncture (CLP). N=7-8. Data are shown
Mean ± SEM.

94

Figure 32: Peritoneal IL-10 after Cecal Ligation and Puncture

There is no difference in the peritoneal IL-10 between miRNA-21+/+ and miRNA21-/-mice following cecal ligation and puncture (CLP). N=7-8. Data are shown
Mean ± SEM.
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Discussion
We have shown that after CLP there is an initial down-regulation in MiRNA-21
expression followed by a delayed up-regulation at 48 hours. This is in direct
contrast to LPS, which shows a linear up-regulation of miRNA-21 after
stimulation. This early down-regulation in the macrophages at 6 hours may be
due to a delay in the stimulation of TLR-4 by bacteria migrating from the lumen of
the bowel into the peritoneum. However this would not explain the data from the
24 hour time point.
Exosomes are 40-10nm membrane vesicles that are secreted by cells as part of
cell-cell communication. Recent studies have shown that miRNA-21 is secreted
in exosomes into peritoneal fluid at higher levels in ovarian serous carcinoma
than normal controls

54

. Exosomal miRNA-21 expression has also been up-

regulated in serum in esophageal cancer and cervicovaginal lavage in cervical
cancer

142, 143

. If intra-cellular macrophage miRNA-21 was secreted into the

peritoneum following CLP, this may account for the decreased expression seen
within the cells at 6 and 24 hours.
We observed no difference between miRNA-21+/+ and miRNA-21-/- mice in PEC
cell count, total macrophage count or macrophages as a percentage of the total
number of PEC cells. TNF-α was higher in the peritoneal lavage media from
miRNA-21+/+ mice at 6 hours. All other cytokines were similar regardless of the
presence or absence of miRNA-21.
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These data partially explain why there was no difference in survival observed
between miRNA-21+/+ and miRNA-21-/- mice following induction of peritonitis with
20G CLP. Collectively our data suggest that TLR-4 signaling has a definite role to
play in the innate immune response to peritonitis, though the redundancy of
multiple pathways stimulated in following induction of peritonitis with CLP may
minimize the effects of miRNA-21 in this model.
Although miRNA-21 did not show a survival benefit, we believe that there may
still be a therapeutic role for miRNA-21 in a clinical setting. Further experiments
are required to ascertain the presence and pattern of exosomal or free miRNA-21
in peritoneal fluid, both in the normal and infected abdomen. Examination of
abdominal washings or drain fluid in post-operative surgical patients, will likely
yield novel data about the role of miRNA-21 in peritonitis. Although knockout of
miRNA-21 was not effective in changing survival, there may be a role for
increasing miRNA-21 expression within the peritoneum to affect the severity of
infection without affecting mortality rate.

.
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CHAPTER XI
CONCLUSIONS AND OVERVIEW
The early innate immune response to invading microbes during peritonitis is
largely orchestrated by the peritoneal macrophage. These cells have three basic
functions:

phagocytosis,

antigen

presentation,

and

protein

secretion.

Macrophages have been classed into two phenotypes - M1, the classical or proinflammatory macrophage that produces TNF-α, IL-1, IL-6, nitric oxide and has
strong microbial activity, and M2 or alternatively activated macrophages that
produce IL-10, Arginase-1 and Mrc1 (CD206) and are involved in preventing
excessive injury in the host tissue remodeling

144, 145

. Macrophages can be

converted from one phenotype into another. The key transcription factors
involved in macrophage polarization are STATs, NF-κB, and camp-responsive
element-binding protein (CREB). Therapeutic targeting to change the polarization
of macrophages is still in the primordial phase of development, but the
microenvironment and anatomical location of the cells are important

145, 146

. We

have shown that miRNA-21 modulates the cytokine output of peritoneal
macrophages, from a pro- to anti-inflammatory profile, suggesting that miRNA-21
is involved in macrophage polarization. The reduction in TNF-α and IL-6 together
with the increase observed in IL-10 production in response to LPS with increased
miRNA-21 may indicate a role in the transition of macrophages to a M2
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alternative activation state. Further characterization of whether there is any
difference in the M2 expressed genes such as Arginase-1, chitinase 3-like 3
(Ym1), and Mrc1 (CD206) between miRNA-21-/- and miRNA-21+/+ cells should
yield novel data to clarify the active mechanisms involved in the transition of the
early innate immune response to peritonitis.
Indeed, a study of microbial tolerance has shown that a LPS-tolerant state leads
to a M2 polarized phenotype in macrophages

104

, and the NF-κB p50 subunit is

the key regulator in this transformation. Our experiments focused on the p65
subunit, and this may contribute to why differences in the activation of NF-κB
were not observed in these experiments.
Recent reports in the literature have postulated an early/acute hyperinflammatory and a late/chronic hypo-inflammatory phase in response to sepsis
84, 113, 147, 148

. This immunosuppression phase in late sepsis leads to mortality

from persisting primary infection or an opportunistic new infection, otherwise
known as the two hit model. Some data suggest that altered myeloid maturation
or differentiation may be important. Adoptive transfer of CD34+ hematopoietic
stem-progenitor cells after CLP improved survival by 65%. Cell transfer resulted
in no change in the early hyper-inflammatory response, but corrected the later
immunosuppression,

increasing

circulating

pro-inflammatory

cytokines,

enhancing phagocytic activity and clearing bacterial peritonitis. It is likely that
these new cells differentiated into competent immune cells in the blood and
tissue, reversing or replacing hyporesponsive endotoxin-tolerant cells in the
peritoneum

149

. We have no current data about the role of miRNA-21 in this late
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stage of sepsis, though theoretically if it is still active, then inhibition of miRNA-21
to change to a more pro-inflammatory response maybe potentially beneficial.
There are numerous limitations on this work. The isolation process may have
activated macrophages, though we tried to counteract any effects by using a
gentle process and resting the cells for 24 hours prior to use to alleviate some of
these effects on subsequent stimulation. Bone marrow derived macrophage cell
lines were used to evaluate the absence of miRNA-21, however these
macrophages are an immortalized cell line, which are not primary peritoneal
macrophages. These cells are likely to be phenotypically or genetically different
from primary peritoneal macrophages and therefore are only able to approximate
what is occurring in the peritoneum. The evaluation of the individual cell type
responses in vitro also need to be related to what in occurring in vivo as cells do
not respond alone, multiple cells types communicate and respond to infectious
stimuli together.
In conclusion, we found that miRNA-21 expression increases in macrophages
after LPS stimulation. MiRNA-21 decreases TNF-α and IL-6 production, while
increasing IL-10. The mechanism by which the expression of these cytokines
was modulated is not clear from these experiments. PDCD4 has emerged as the
most likely target protein to be effecting the cytokine modulation, though NF-κB
activation was not different.
MiRNA-21 is beneficial in survival from an LPS model of peritonitis but not after
CLP, as it does not have sufficient power to change the peritoneal cytokine
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profile that is associated with mortality. Although miRNA-21 did not change
survival after CLP, there may still be a therapeutic role in peritonitis that warrants
further investigation. If miRNA-21 can ameliorate the severity of infectious
sequelae, that would be clinically beneficial. The healthcare costs involved with
intensive care and multi-organ support are significant. Reducing admission to or
length of stay in the intensive care unit would positively impact the care of
patients with peritonitis.
MiRNA-21 is present in plasma and peritoneal fluid

50, 54, 150

. There are currently

no data on the presence and pattern of exosomal or free miRNA-21 in peritoneal
fluid, in either the normal or infected abdomen. Isolation of miRNA-21 from perioperative abdominal washings undergoing abscess drainage or drain fluid in
post-operative surgical patients would improve our understanding of the course
of miRNA-21 secretion in response to clinical peritonitis. Future animal
experiments could determine if the addition of exogenous miRNA-21 to the
peritoneum after CLP is able to modulate the local immune response in vivo.
We hypothesized that the outcome of peritonitis can be modulated by miRNA-21
through down regulation of NF-κB signaling that affects macrophage cytokine
release, to diminish local inflammation. These findings demonstrate that although
miRNA-21 is beneficial in modulating the macrophage response to LPS, the
effect is buried in the multiple pathways activated after the clinically more
relevant model of CLP. The improved understanding of the anti-inflammatory
effects of miRNA-21 in macrophage response to peritonitis may result in a
targeted therapy to intervene in clinical peritonitis.
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APPENDIX: ABBREVIATIONS
General Abbreviations
APACHE

Acute Physiology and Chronic Health Evaluation

CLP

Cecal Ligation and Puncture; peritonitis model

DIC

Disseminated Intravascular Coagulation

ELISA

Enzyme Linked Immunosorbent Assay

PEC

Peritoneal Exudate Cells

Cell Biology
CREB

CAMP-responsive Element-Binding Protein

ceRNA

Competing Endogenous RNA

cDNA

Complementary DNA

mRNA

Messenger RNA; longer, single stranded RNA; template for protein
translation

miRNA

MicroRNA; short single stranded RNA

Peli1

Pelino1; target of miRNA-21
125

PDCD4

Programmed Cell Death Protein 4; target of miRNA-21

RAW264.7

Mouse macrophage cell line

RISC

RNA-Induced Silencing Complex

siRNA

Silencing RNA; prevents translation of target mRNA into protein

SPRY

Sprouty; target of miRNA-21

Immunology
CD206

Cluster of Differentiation 206; marker of M2 macrophages

DAMP

Damage Associated Molecular Protein

IL-6

Interleukin-6; pro-inflammatory cytokine

IL-10

Interleukin-10; anti-inflammatory cytokine

LPS

Lipopolysaccharide; part of the outer membrane of gram-negative
bacteria; a DAMP

PAMP

Pathogen Associated Molecular Protein; bacterial or viral peptide
recognized by the immune system

PRR

Pattern Recognition Receptor; receptors that recognize DAMPs
and PAMPs

TLR

Toll-Like Receptor; a PRR

126

TNF-α

Tumor Necrosis Factor-α; pro-inflammatory cytokine

Pathway
ELK1

part of the MAPK pathway

ERK

Extracellular Signal Related Kinase; part of the MAPK pathway and
important for IL-10 production

IKK

Inhibitory Kappa Kinase; activator of NF-κB IκB

IκB

Inhibitory kappa protein Beta

IRAK

IL-1 Receptor Associated Kinase; central signaling protein of the
TLR-4 pathway

JNK

c-Jun N-terminal Kinase

MAPK

Mitogen Activated Protein Kinases pathway; part of the TLR-4
signaling pathway

MyD88

Myeloid Differentiation Primary Response Gene 88; central
signaling protein of TLR-4

NF-κB

Nuclear Factor Kappa Beta; transcription factor of TLR-4 signaling

RIP1

TRIF-signaling adaptor kinase; interacts with Peli1

TRAF6

TNF-Receptor Associated Factor; central signaling protein of TLR-4
pathway
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TRAM

TRIF-related Adapter Molecule

TRIF

TIR-domain-containing adaptor-inducing interferon β

128

CURRICULUM VITAE

Personal details:
Rebecca Elise Barnett

D.O.B: 02/05/1982

1639 Jaeger Avenue

email: rebarn02@louisville.edu

Louisville
Kentucky 40205

US mobile: +1 502 777 9661

USA

Education:
University of Louisville

2012 - 2014

Bournemouth University

2007-2008

Imperial College School of Medicine

2000-2006

Qualifications:
Membership of Royal College of Surgeons
PG Cert in Professional Practice: Medicine
MBBS

2010
Merit
Merit in Pharmacology

BSc in Medical sciences with Haematology
129

2:1

2008
2006
2004

Current Post:
Research Fellow at University of Louisville and Robley Rex Veterans Affairs
Hospital, Louisville, Kentucky, USA to Dr. William G. Cheadle. Additional
Mentors: Dr. Susan Galandiuk and Dr. Hiram C. Polk Jr.

Previous Appointments:
Aug 2011 – Sept 2011

General and Colorectal Surgery Trust Grade SHO

Mr Nick Markham; Mrs Katie Cross; Mr Mark Cartmell; Mr Anjum Arain
North Devon District Hospital
Feb 2011 – Aug 2011

Orthopaedics CT2

Mr Colin Steinlechner
Aug 2010 – Feb 2011

North Devon District Hospital
General and Colorectal Surgery CT2

Mr Nick Markham; Mrs Katie Cross; Mr Mark Cartmell; Mr Anjum Arain
North Devon District Hospital
Feb 2010 – Aug 2010

General and Vascular Surgery CT1

Mr Afzaal Ahmad; Mr John Taylor
Aug 2009 – Feb 2010

Emergency Medicine CT1

Mr Mike Roberts
Dec 2009 – Jun 2010

North Devon District Hospital

North Devon District Hospital
Medical Registrar

Dr Paul Laird; Dr John Burrell

Lismore Base Hospital, Australia

130

Oct 2009 – Dec 2009

Emergency Medicine RMO

Dr Chris Gavaghan;
Sept 2009 – Oct 2009

Lismore Base Hospital
Medicine and Haematology Oncology Resident
Medical Officer (RMO)

Dr David Jackson; Dr Adam Boyce
Apr 2009 – Aug 2008

Lismore Base Hospital

Haematology F2

Dr Andrew Bell; Dr Jason Mainwaring; Dr Fergus Jack
Poole General Hospital
Dec 2007 – April 2008

Dermatology and Rheumatology F2

Dr Selwyn Richards;
Aug 2007 – Dec 2007

Poole General Hospital
General and Breast Surgery F2

Mr James Pain;
Apr 2007 - Aug 2007

Poole General Hospital
Medicine and Endocrinology F1

Dr Mike Masding;

Jan 2007 – Apr 2007

Poole General Hospital

Medicine and Gastroenterology F1

Dr Nick Sharer;
Dec 2006 – Jan 2007

Poole General Hospital
Medical Assessment Unit F1

Dr Mike Masding;
Aug 2006 – Dec 2006

Poole General Hospital
General and Upper GI Surgery F1

Mr Shorland Hosking;

Poole General Hospital

131

Publications:
1. Foundation Programme Assessments. Barnett RE, Hall SM, Masding
MG. Clinical Tutor, 2008;13 (1)
2. MicroRNAs as a New Factor in Lung and Esophageal Cancer. Billeter AT,
Barnett RE, Druen DW, Van Berkel VH, Polk Jr HC. Seminars in Thoracic
Surgery. 2012 Autumn; 24(3):155-65.
3. Differential MicroRNA Expression Could Explain Microbial Tolerance in a
Novel Chronic Peritonitis Model. Kanaan Z, Barnett R, Gardner S, Keskey
B, Druen DW, Billeter AT, Cheadle WG. Innate Immunity. Innate Immunity.
2013;19(2);203-12.
4. A Natural Immunomodulator Attenuates the Systemic Inflammatory
Response in Polymicrobial Peritonitis. Love K, Barnett RE, Holbrook I,
Peyton J, Sonnenfeld G, Cheadle WG. Journal of Trauma and Acute Care
Surgery. 2013 Jun; 74 (6):1411-18.
5. Accuracy of Computerized Tomography in Small Bowel Obstruction.
Barnett RE, Younga J, Harris B, Keskey RC, Nisbett D, Perry J, Cheadle
WG. American Surgeon. 2013 Jun; 79 (6):641-3.
6. Poor Outcome in Bacterial Peritonitis is Associated with Dysregulated
MicroRNAs and an Increased Inflammatory Response. Barnett RE,
Keskey RC, Rao JM, Billeter AT, Kanaan Z, Cheadle WG. Surgery. 2013
Sep; 154(3):521-7.

132

7. Tension Free Open Mesh Cooper's Ligament Repair for Femoral Hernia.
Barnett RE, Keskey RC, Byam J, Linsky PL, Mathis T, Cheadle WG.
American Surgeon - Brief Report. 2013 Sep;79(9):952-3.
8. “Never Say Never Again” SIS Presidential Address 2013
Cheadle WG, Barnett RE.
Surgical Infection, 2014 Apr 30 Epub ahead of print
9. Small Bowel Trauma: Current Thinking in Diagnosis and Management
Barnett RE, Love K, Sepulveda EA, Cheadle WG
American Surgeon – Invited Review, In Press
10. Cecal Diverticulitis Mimicking Cecal Carcinoma
Barnett RE, Rao JM, Ryan LE, Cheadle WG.
American Surgeon – Brief Report EPub
11. Damage Control for Thoracic Trauma
Mackowski MJ, Barnett RE, Harbrecht BG, Miller KR, Franklin GA, Smith
JW, Richardson JD, Benns MV.
American Surgeon. In Press
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Book Chapters:
1. Surgical Immunology Chapter. Cheadle WG, Billeter AT, Kanaan Z,
Barnett RE.
Surgical Infection. Editor: Dr. Donald Fry. 2013.
2. Surgical Infection. Barnett RE & Cheadle WG – Associate Editors.
Selected Reading in General Surgery. Editor: Dr. Lewis Flint. 2013 Aug;
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Presentations:
International
1. Expression of MiR-21 is advantageous in the Immune Response to
Peritonitis
Barnett RE, Sepulveda E, Cheadle WG.
Plenary Session. Surgical Infection Society, Baltimore, MD

May 2014

2. Secondary Bacterial Peritonitis in a Veteran Population – Poster
Barnett RE, Tabler BL, Rao JM, Cheadle WG.

May 2013

Surgical Infection Society – Europe, Prague, Czech Republic
3. Cecal Diverticulitis Mimics Cecal Cancer - Poster
Barnett RE, Rao JM, Mathis T, Cheadle WG.
Surgical Infection Society – Europe, Prague, Czech Republic
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May 2013

4. Large Bowel Pathology presenting as Small Bowel Obstruction is
associated with a Poor Prognosis
Barnett RE, Younga JR, Cheadle WG.
VA Surgeons, Milwaukee, WI

Apr 2013

5. MicroRNA Expression in the Innate Immune Response to Peritonitis Poster
Barnett RE, Keskey RC, Ryan LE, Rao JM, Cheadle WG
Surgical Infection Society, Las Vegas, NV

Apr 2013

6. Computerized Tomography in Small Bowel Obstruction
Barnett RE, Younga J, Harris B, Keskey RC, Nisbett D, Perry J, Cheadle
WG.
South Eastern Surgical Congress, FL

Feb 2013

7. Poor Outcome in Bacterial Peritonitis is Associated with Dysregulated
MicroRNAs Resulting and an Increased Inflammatory Response
Barnett RE, Keskey RC, Billeter AT, Cheadle WG.

Feb 2013

Academic Surgical Congress (Combined meeting of Society of University
Surgeons and Association for Academic Surgery), New Orleans,

LA

8. Dysregulation of miR-132 and -21 reduces IL-1 β levels in a novel model
of chronic peritonitis.
Association of Veterans Affairs Surgeons, Miami Beach, FL Apr 2012
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9. Tension Free Open Mesh Cooper’s Ligament Repair for Femoral Hernia Poster
Keskey RC, Barnett RE, Byam J, Linsky P, Cheadle WG.
South Eastern Surgical Congress, AL

Feb 2012

Regional
10. Targets of MicroRNA-21 in Peritoneal Macrophages After LPS Stimulation
– Poster
Keskey RC, Rao JM, McKinley I, Lawson C, Barnett RE, Cheadle WG.
Research Louisville!
11.

Sept 2013

MicroRNA Expression in Murine Cecal Ligation and Puncture Model Poster
Ryan LE, Barnett RE, Keskey RC, Cheadle WG
Research Louisville!

Sept 2012

12. MicroRNA Expression in the Innate Immune Response to Peritonitis Poster
Rao JM, Barnett RE, Keskey RC, Cheadle WG
Research Louisville!

Sept 2012
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13. Poole experience of NEW START Sentinel Lymph Node Biopsy
programme.
Barnett RE, Evans A.
Wessex Breast Meeting.

Oct 2007

Local
14. The Role of MicroRNA-21 in the Regulation of the Early Innate Immune
Response to Peritonitis

Nov 2013

Department of Molecular Cardiology Seminar, University of Louisville
15. The Role of MicroRNA-21 in the Regulation of the Early Innate Immune
Response to Peritonitis
Price Seminar at Price Institute of Surgical Research, University of
Louisville

Jun 2013

16. MicroRNAs in the Innate Immune Response to Peritonitis
Department of Physiology Seminar, University of Louisville
Jan 2013
17. The National Health System: A British Institution

Feb 2012

Price Seminar at Price Institute of Surgical Research, University of
Louisville
18. Supracondylar fractures of the humerus in children audit
Orthopaedic Teaching at North Devon District Hospital
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Jul 2011

19. Masssive Blood Transfusion Protocol re-audit

Jul 2011

Surgical and Anaesthetic Clinical Goverance Meeting, North Devon
District Hospital
20. Pelvic Fractures

Jul 2011

Surgical and Anaesthetic Clinical Goverance Meeting, North Devon
District Hospital
21. Bilateral Inguinal Hernia: Laparoscopic or open approach

Dec 2010

Journal club, South West registrar training day, North Devon District
Hospital.
22. To die with dignity.

Nov 2010

Surgical teaching session at North Devon District Hospital.
23. Massive blood transfusion protocol audit.

Apr 2010

Surgical and Anaesthetic Clinical Governance Meeting, North Devon
District Hospital.
24. Fibrinolysis in Acute Myocardial Infarction.

Jan 2009

Emergency Department Registrar teaching, Lismore Base Hospital
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Research
MicroRNA-21has Anti-Inflammatory Effects in the Macrophage Response to
Peritonitis
PhD Thesis

Aug 2012 – Aug 2014

Using mouse models of peritonitis we have been investigating the effects of over
and underexpression of microRNA-21 in the macrophage response.

Small Bowel Obstruction

Jan 2012 – Aug 2014

Using our database of patients admitted to University Hospital with small bowel
obstruction we have looked at predictors of mortality and the accuracy of
computerised tomography.

MicroRNA Dysregulation and Outcome in Bacterial Peritonitis
Feb – Aug 2012
Using a novel model of chronic peritonitis we looked at microRNA expression in
the peritoneum in predicted survivors compared to predicted deaths.

MicroRNA Expression in Microbial Tolerance

Oct 2011 – Feb 2012

Using a novel model of chronic peritonitis we looked at microRNA expression in
the peritoneum of mice following the induction of microbial tolerance.

Analysis of Centrosomal Proteins in Chronic Lymphocytic Leukaemia
BSc project

March - May 2004
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Expression of TACC3 centrosomal protein in patients with chronic lymphocytic
leukaemia compared to other white cell diseases.

Skills in Molecular Biology
Cell Culture
Magnetic Bead Isolation
RNA Isolation
Polymerase Chain Reaction for messenger and microRNA.
Protein quantification
Enzyme-linked Immunosorbent Assay (ELISA)
Western Blot
Immunofluorescence
Transfection of microRNA into peritoneal macrophages
Animal Handling and Injections
Caecal Ligation and Puncture
Harvest of Peritoneal Cells, Blood and Tissues (Lung, Liver, Cardiac)
Bacterial plating and quantification
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Audits:
Supracondylar Fractures of the Humerus in Children

Jul 2011

Role: Audit design, data analysis and write up.
Loop closed: No.
Standards: Guidelines from O’Hara et al J Bone Joint Surg [Br] 2000.
Performed: North Devon District Hospital, Barnstaple, Devon.
Results: Presented at Orthopaedic teaching.

Massive Blood Transfusion Protocol

Feb 2011

Role: Audit design, data analysis and write up.
Loop closed: Yes.
Standards: Local Guidelines
Performed: North Devon District Hospital, Barnstaple, Devon.
Results: Presented at Anaesthetic & Surgical and Medical Clinical Governance
meetings.

Fibrinolysis in acute myocardial infarction

Dec 2008

Role: Audit design, data analysis and write up.
Loop closed: Yes, July 2009, following my departure.
Standards: Local Network Guidelines
Performed: Lismore Base Hospital, Lismore, New South Wales, Australia.
Results: Presented at Emergency Department and Registrar teaching.
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Thromboprophylaxis in high risk patients

Jun 2008

Role: Data collection, analysis and write up.
Loop closed: Yes, Dec 2008, following my departure.
Standards: Department of Health Guidelines
Performed: Poole General Hospital, Poole, Dorset.
Results: Presented at local clinical governance meeting.

Clinical Experience:
I am happy running general surgical on-calls including vascular surgery. I have
experience looking after patients in outpatient clinics, and on the wards. I have
experience preparing the patient for surgery, directing peri-operative care in
theatre, and managing them on the ward, including recognising and treating
common post-operative complications.
I am happy diagnosing and managing simple cutaneous abscesses, appendicitis,
peritonitis, gallstone disease, including deciding for surgical intervention, and can
perform incision and drainage of abscess and appendicectomies, laparoscopic
and open with supervision. I can also perform laparoscopic cholecystectomies
with direction.
I have experience running trauma calls in a level 2 trauma centre.
My 6 months spent working as medical registrar in Australia has given me
experience running medical on-calls, and performing medical reviews on surgical
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and orthopaedic patients, recognising and managing medical problems in
surgical patients.

Continuing Medical Education (CME):
Attendance at Grand Rounds and Price Institute of Surgical Research Seminars
Jan 2012-present
Principles of Clinical and Translational Research

Aug

2012

Teach the Teachers

Jul

2011

CCrISP

Jun

2011

Introduction to Medical Education

Feb

2011

ATLS

Jun

2010

Basic Surgical Skills

Mar

2008

M27 Course (Coloproctology)

Nov

2007

Introduction to ENT

Sept 2007

Advanced Life Support

Nov

2006

ALERT

Jul

2006

143

Teaching:
I have experience of teaching medical students and more junior doctors in a
clinical environment, making use of available patients to teach about history
taking, presentation and examination techniques. I have also taught medical and
work experience students in a theatre environment, educating about the surgical
experience and surgical technique.
I have planned formal teaching sessions for Foundation Doctors, using both
lecture based, and more interactive methods.
I have used laparoscopic training devices with colleagues to show and
encourage work experience students about careers in medicine and surgery as
part of a wider curriculum.
I have aided colleagues and nursing staff with skills such as ECG and arterial
blood gas interpretation, intravenous cannulation, catheterisation and suturing by
demonstrating and then supervising the procedures.
As part of the BBC 999 Roadshows I have taught basic resuscitation skills to
members of the general public.
I undertook modules on teaching and learning as part of my regional F2 study
days at Bournemouth University. I have also undertaken courses on medical
education and teaching specific to medicine in order to improve my teaching
skills. This has given me specific tips and practice planning teaching session as
well as dealing with different and difficult situations.
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I also enjoy educating patients about their diseases and prognosis in language
that they can understand, taking time to answer their questions and drawing
diagrams to aid comprehension.
In my 2 years as Research Fellow in the Price Institute of Surgical Research I
have taught many undergraduate and medical students research techniques,
analysis of data and how to construct and present research data.

Management:
Research Fellow

Oct 2011

As the research fellow within the Veterans Affairs Surgical Research Laboratory,
I organise and plan experiments. I order needed reagents and animals, ensure
the laboratory meets all federal and national safety requirements and train and
supervise my undergraduate and medical student laboratory assistants.
I have collaborated with multiple principle investigators across research
specialities and co-ordinated research plans for projects using knockout mice.

VTE Committee Member

Nov 2009

Junior Doctor Representative on North Devon District Hospital Venous
Thromboembolism Committee, introducing new VTE risk assessment forms
throughout the trust, and their integration into new drug charts.
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Rota Co-ordinator

Oct 2008

Involved in developing new surgical rota with change of staffing levels. Managed
Surgical Junior rota and annual leave.

Organised ALS courses for all F1s at Poole.

Nov 2007

Regatta Director for Bournemouth Lifeguard Corps

Jul 2007

Organised the Bournemouth Lifeguards Regatta, a two day National Beach
Lifeguarding Competition, with 13 teams of six people from around the country
competing in a variety of events. The events use many lifeguard skills including
incidents (in the sea and on land), first aid, reel & line, rope throwing, knots, iron
man, canoeing, torpedo relay and other unique events.

The competition is

organised in such a way that every member of the team is involved throughout
the weekend and every member of the team should be proficient in the wide
variety of skills.
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Meetings
Surgical Infection Society – North America, Baltimore, MD

Apr 2014

Southeastern Surgical Congress, Savannah, GA

Feb 2014

American College of Surgeons, Washington DC

Oct 2013

Surgical Infection Society – Europe, Prague, Czech Republic

May 2013

Association of Veterans Affairs Surgeons, Milwaukee, WI

Apr 2013

Surgical Infection Society – North America, Las Vegas, NV

Apr 2013

Southeastern Surgical Congress, Jacksonville, FL

Feb 2013

Academic Surgical Congress, New Orleans, LA

Feb 2013

Association of Veterans Affairs Surgeons, Miami Beach, FL

Apr 2012

Southeastern Surgical Congress, Birmingham, AL

Feb 2012

Going Overseas Network, Bristol

Sept 2011

Societies
Surgical Infection Society – North America

Jun 2013

Women In Surgery (WinS)

Aug 2010

Association of Surgeons in Training (ASIT)

Jan 2010
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IT:
I am comfortable using Microsoft Office, and have a GSCE (short Course) in
Information Technology. I am familiar with several variations on PACS and
pathology results systems. I regularly use the internet to access electronic
journals and online information. I have experience using Sigma plot to statistically
analyse data and create graphs to aid comprehension.

Extra-Curricular:
I enjoy Salsa and Swing dancing, climbing both indoors and outdoor, especially
Winspit, on the Isle of Purbeck, Dorset. I learnt to surf when living in Byron Bay,
Australia, a pastime I was able to continue whilst living in North Devon. I also
enjoy scuba diving, first dipping my feet off the coast of Kenya, and going on to
become a qualified PADI open water in Thailand. I have since dived in the UK,
South Africa, and Australia and achieved my advanced open water diver award
in Grenada.

Career Plan:
I am working towards becoming a Consultant General Surgeon with an interest in
both bench and clinical research in the field of peritonitis. I have an interest in
upper gastrointestinal surgery, with laparoscopic surgery and hernias. My
elective in Ghana has also given me the wish to work in Africa in the future, when
I have an appropriate surgical skill base.
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